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ABSTRACT  
 
Background. Cartilage-hair hypoplasia (CHH) is a rare chondrodysplasia with short stature, 
hair hypoplasia, combined immunodeficiency and increased risk of malignancy. The non-
coding RNA gene RMRP is mutated in CHH, which leads to several cellular derangements, 
including cell cycle impairment. However, the spectrum and evolution of the clinical 
manifestations and the pathogenesis of CHH are incompletely understood. The degree of 
immunodeficiency is highly variable, and previous studies have failed to establish clear clinical 
or laboratory correlates of disease severity. Patients with CHH display increased mortality 
due to infections and malignancies, however, factors associated with mortality remain 
unrecognized. Respiratory infections can induce the development of bronchiectasis, but lung 
changes have not been systematically studied in CHH. 
Objectives. We performed detailed immunologic evaluation of a large cohort of patients with 
CHH, explored the prevalence of bronchiectasis and compared diagnostic lung imaging 
modalities, and conducted a prospective long-term follow-up study to identify factors 
associated with adverse outcomes. We also investigated the role of telomere machinery in 
the pathogenesis of CHH. 
Subjects and methods. We repeatedly recruited Finnish CHH patients, identified through the 
Finnish Chondrodysplasia Registry (n = 104-110), and included all subjects who consented to 
participate (n = 56-80). Patients were interviewed and clinically examined, and blood samples 
were collected. Additional data were obtained from hospital records, the Finnish National 
Health Databases, the Cancer Registry and the Cause-of-death Registry of Statistics Finland. 
We evaluated patients' blood samples for a range of immunologic parameters (n = 56), and 
for relative telomere length (RTL) by quantitative-PCR method (n = 48). Blood samples from 
the first-degree relatives and DNA samples from healthy controls were also used for RTL 
measurements. A subgroup of patients (n = 34) underwent lung imaging by high-resolution 
computed tomography (HRCT) and magnetic resonance (MRI). 
Results. Common immunological findings in 56 patients with CHH included: 1) decreased 
thymic naive, naive CD4+ and CD8+ T cells; 2) increased activated CD4+, central memory CD4+ 
and effector memory CD8+ T cells; 3) normal regulatory T cells; 4) decreased naive, 
transitional and memory B cells; 5) increased activated B cells. Specific antibody deficiency 
was demonstrated in the majority of patients immunized with unconjugated 23-valent 
pneumococcal vaccine (Pneumovax®). No significant correlations were observed between 
clinical and laboratory features. Patients with CHH demonstrated significantly shorter median 
RTL compared with healthy controls. RTL correlated with age in carriers and non-carriers of 
RMRP mutations, but not in patients, due to the shorter telomeres in children with CHH. HRCT 
showed bronchiectasis in 10/34 patients (29%) and MRI scores correlated significantly with 
HRCT scores. In the prospective study of 80 subjects with CHH, the median duration of follow-
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up for the surviving patients was 29.2 years (range 25.6 – 31.0 years). In a significant 
proportion of patients (17/79, 22%), clinical features of immunodeficiency progressed over 
time, including six cases of adult-onset immunodeficiency. Of the 15 subjects with non-skin 
malignancy, eight demonstrated no preceding symptoms of immunodeficiency. Altogether 
20/80 patients had died during the follow-up, and causes of death included pneumonia (n = 
4), malignancy (n = 7) and pulmonary disease (n = 4). Increased mortality was associated with 
severe short stature at birth, Hirschsprung disease, pneumonia, autoimmunity and symptoms 
of combined immunodeficiency. In addition, warts in adulthood and actinic keratosis were 
associated with the development of skin cancer. Patients with shorter birth length developed 
malignancy at an earlier age.  
Conclusions. Study patients demonstrated specific abnormalities in B and T cell 
compartments. Antibody responses to polysaccharide antigens were impaired in the majority 
of tested patients. Clinical features did not correlate with laboratory parameters. Patients 
with CHH showed high prevalence of bronchiectasis, and lung evaluation is indicated also in 
those without apparent immunodeficiency. Lung MRI was comparable to HRCT in the 
assessment of bronchiectasis and can be implemented in the follow-up of lung changes. 
Telomere length was decreased in subjects with CHH, especially children. Patients with CHH 
demonstrated high mortality due to infections and malignancies, but also from lung disease. 
Some subjects presented with adult-onset immunodeficiency or malignancy without 
preceding symptoms of disrupted immunity, warranting careful follow-up and screening for 
cancer even in asymptomatic patients. We provided clinicians with the risk factors for adverse 
outcomes to assist in management decisions and we suggested implication of our results for 
the management of Finnish patients with CHH.  
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TIIVISTELMÄ 
 
Tausta. Rusto-hiushypoplasia (RHH) on harvinainen luustodysplasia, jonka oireisiin kuuluvat 
kasvuhäiriön lisäksi hiusten hentous, kombinoitu immuunipuutos ja lisääntynyt syöpäriski. 
RHH johtuu ei-koodaavan RNA-geenin RMRP-mutaatioista, joiden seurauksena solusykli 
häiriintyy, mutta taudin tarkempia mekanismeja ei vielä ymmärretä. Immuunipuutoksen aste 
on erittäin vaihteleva eikä aiemmissa tutkimuksissa ole pystytty osoittamaan kliinisten 
oireiden tai laboratorioarvojen yhteyttä taudin vaikeusasteeseen. RHH:aa sairastavilla 
potilailla on lisääntynyt kuolleisuus infektiotauteihin ja maligniteetteihin, mutta 
kuolleisuuteen vaikuttavia tekijöitä ei tunneta. RHH:aa sairastaville potilaille, joilla on 
hengitystieoireita, voi kehittyä bronkiektasioita, mutta keuhkojen muutoksia RHH:ssa ei ole 
tutkittu järjestelmällisesti. 
Tutkimuksen tarkoitus. Suoritimme yksityiskohtaisia immunologisia tutkimuksia laajassa 
RHH:aa sairastavien potilaiden kohortissa. Tutkimme bronkiektasioiden esiintyvyyttä ja 
keuhkojen eri kuvantamismenetelmiä. RHH-potilaiden kuolleisuuteen ja 
syöpäsairastumiseen liittyvien tekijöiden tunnistamiseksi suoritimme potilaille 30 vuoden 
seurantatutkimuksen. Tutkimme myös telomeerien roolia RHH:n patogeneesissä. 
Aineisto ja menetelmät. Suomen Luustodysplasiarekisterin kautta tunnistettiin toistuvasti 
Suomen RHH:aa sairastavat potilaat (n = 104–110), joista tutkimukseen mukaan otettiin 
kaikki suostumuksensa antaneet (n = 56–80). Potilaita haastateltiin ja tutkittiin kliinisesti ja 
heiltä otettiin verinäytteitä. Lisätietoja kerättiin potilaiden sairaskertomuksista, Hilmo- ja 
Avohilmo-järjestelmästä ja Syöpärekisteristä sekä Tilastokeskuksesta. Potilaiden 
verinäytteistä tutkittiin useita immunologisia parametreja (n = 56) sekä suhteellinen 
telomeerien pituus (STP) kvantitatiivisella PCR-menetelmällä (n = 48). STP mitattiin myös 
potilaiden ensimmäisen asteen sukulaisten verinäytteistä ja terveiden henkilöiden DNA-
näytteistä. Osalla potilaista (n = 34) kuvattiin keuhkoja tietokonetomografialla (TT) ja 
magneettikuvauksella (MK).  
Tulokset. Tyypilliset immunologiset löydökset 56 potilaan kohortissa olivat: 1) vähentyneet 
tyymus-naiviit, naiivit CD4+ ja CD8+ -T-solut, 2) lisääntyneet aktivoituneet CD4+, 
keskusmuisti-CD4+ ja efektorimuisti-CD8+ -T-solut, 3) normaalit regulatoriset T-solut, 4) 
vähentyneet naiivit, transitionaalit ja muisti-B-solut, 5) lisääntyneet aktivoidut B-solut. 
Spesifinen vasta-ainepuutos osoitettiin suurimmalla osalla potilaista, jotka olivat saaneet 23-
valenttisen, ei-konjugoidun pneumokokkirokotteen (Pneumovax®). Oireiden ja 
laboratorioarvojen välillä ei havaittu merkittäviä korrelaatioita. Mediaani-STP  oli potilailla 
huomattavasti lyhyempi kuin verrokeilla. STP korreloi iän kanssa RMRP-mutaatioiden 
kantajilla ja ei-kantajilla, mutta ei potilailla, johtuen lyhyemmistä telomeereista RHH:aa 
sairastavilla lapsilla. TT-kuvauksella todettiin bronkiektasioita 10/34 potilaalla (29 %), ja MK 
tulokset korreloivat merkittävästi TT-tulosten kanssa. 80 potilaan prospektiivisessa 
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tutkimuksessa mediaaniseurannan kesto oli 29,2 vuotta (vaihtelu 25,6–31,0 vuotta). 
Merkittävällä osalla potilaista (17/79, 22 %) immuunipuutos eteni ajan myötä; kuudelle heistä 
kehittyi myöhäinen immuunipuutos aikuisiässä. Yli puolella syöpään (ihosyöpä pois lukien) 
sairastuneista potilaista (8/15, 53 %) ei ollut edeltäviä immuunipuutoksen oireita. Seurannan 
aikana kuoli yhteensä 20/80 potilasta, mm. keuhkokuumeeseen (4), syöpään (7) ja 
keuhkosairauksiin (4). Kuolleisuuteen liittyi useita riskitekijöitä, mukaan lukien lyhyempi 
syntymäpituus, Hirschsprungin tauti, keuhkokuume, autoimmuunitaudit ja kombinoitu 
immuunipuutos. Lisäksi aikuisiän syylillä ja aurinkokeratoosilla oli  yhteyttä ihosyövän 
kehittymiseen. Ne potilaat, joiden syntymäpituus oli lyhyempi, sairastuivat maligniteettiin 
nuoremmalla iällä. 
Johtopäätökset. Potilailla osoitettiin tiettyjä poikkeavuuksia B- ja T-soluissa. Useimmilla 
potilailla vasta-ainevasteet polysakkaridiantigeeneja kohtaan olivat heikentyneitä. Oireiden 
ja laboratorioparametrien välillä ei havaittu merkittäviä yhteyksiä. Potilailta löytyi usein 
bronkiektasioita, ja keuhkojen arviointi on aiheellista myös niillä, joilla ei ole 
immuunipuutoksen merkkejä. Keuhkojen MK-tulokset olivat verrattavissa TT-tuloksiin 
bronkiektasioiden arvioinnissa, ja MK:ta voidaan käyttää keuhkomuutosten seurannassa. 
Telomeerit olivat lyhyempiä RHH:aa sairastavilla potilailla, erityisesti lapsilla. Potilailla oli 
korkea kuolleisuus infektioihin ja maligniteetteihin, mutta myös keuhkosairauksiin. Osalle 
potilaista kehittyi myöhäinen immuunipuutos tai syöpä ilman edeltäviä merkkejä 
häiriintyneestä immuniteetista, mikä on peruste tarkkaan seurantaan ja syövän seulontaan 
myös oireettomilla potilailla. Kuvasimme tutkimuksissa useita kuolleisuuden riskitekijöitä, 
jotka helpottavat hoitopäätösten tekemistä ja toimivat perustana suomalaisten RHH:aa 
sairastavien potilaiden hoitosuosituksille. 
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1. INTRODUCTION 
 
Primary immunodeficiency disorders (PID) comprise a heterogenous group of defects in the 
immune system. Several of them, including cartilage-hair hypoplasia (CHH, MIM # 250250), 
present with skeletal dysplasia among other features. 
After the first description by Maroteaux et al in 1963, McKusick et al reported CHH in a series 
of 77 subjects of Amish origin in 1965 (Maroteaux, et al. 1963, McKusick, et al. 1965). These 
studies highlighted the main clinical characteristics of CHH, such as the short-limbed short 
stature, sparse and fine hair, unusual susceptibility to infections and intestinal defects. This 
rare chondrodysplasia was soon recognized to be overrepresented in Finland (Perheentupa 
1972) and further studies described over 100 Finnish patients in 1990s (Makitie 1992, Makitie 
and Kaitila 1993). 
The genetic background for CHH was uncovered in 2001 by Ridanpää et al who showed that 
mutations in the RMRP gene underlie this autosomal recessive disease (Ridanpaa, et al. 
2001). RMRP was the first described disease-associated non-coding RNA gene. RNA 
component of the mitochondrial RNA-processing endoribonuclease (RMRP) is involved in 
gene regulation, rRNA and mRNA processing, and abnormal RMRP function induces the 
impairment of cell proliferation and differentiation (Rogler, et al. 2014, Thiel, et al. 2005). 
However, the pathogenesis of CHH remains poorly characterized. 
Currently, CHH is classified as a syndromic immunodeficiency, in which metaphyseal 
chondrodysplasia is associated with combined immunodeficiency (CID), anemia, hair 
hypoplasia, increased incidence of malignancies and Hirschsprung disease. The incidence of 
CHH is highest among the Amish (1-2 in 1,000 births) and Finnish (1 in 23,000 births) 
populations, outside which CHH is a rare entity, providing a unique opportunity to study this 
disease in Finland (Makitie 1992). 
Immunodeficiency in CHH is highly variable and does not correlate with the type of mutations 
(Kavadas, et al. 2008, Makitie and Kaitila 1993). Except for association between increased 
susceptibility to infections with Hirschsprung disease and shorter birth length (Makitie and 
Kaitila 1993, Makitie, et al. 2001), no prognostic factors in CHH have been described. This 
complicates management decisions and the selection of patients who would benefit from 
early hematopoietic stem cell transplantation (HSCT). 
We addressed the pathogenesis, immunologic phenotype, lung disease and malignancies, 
and factors associated with mortality in patients with CHH. 
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2. REVIEW OF THE LITERATURE 
2.1. Primary immunodeficiency 
 
PID comprise a heterogenous group of over 350 disease entities that are characterized by 
the intrinsic defects in the immune system (McCusker, et al. 2018, Ochs and Petroni 2018, 
Picard, et al. 2018). PID are currently categorized into eight broad categories according to 
the common phenotype: 1) CID, 2) CID with syndromic features, 3) predominantly antibody 
deficiencies, 4) diseases of immune dysregulation, 5) defects of phagocyte number or 
function, 6) defects in intrinsic and innate immunity, 7) autoinflammatory diseases, and 8) 
complement deficiencies (Picard, et al. 2018).  
The increasing number and diversity of PID has shifted diagnostic algorithms towards the 
early implementation of genetic tools (Leiding and Forbes 2019). However, thorough clinical 
history and examination, and measurement of basic laboratory immunologic parameters, 
remain the cornerstone of initial PID diagnostics (Sanchez-Ramon, et al. 2019). Cellular 
immunity is first evaluated with blood counts of neutrophils, lymphocytes, eosinophils and 
monocytes, as well as flow cytometry labeling of lymphocyte subpopulations (CD3+, CD4+ 
and CD8+ T cells, CD19+ B cells and CD16/56+ NK cells), and analysis of lymphocyte 
proliferation responses (Sanchez-Ramon, et al. 2019). Humoral immunity assessment 
includes measurement of serum levels of immunoglobulin (Ig) A, M and G, IgG subclasses 
and antibody responses to vaccines (Sanchez-Ramon, et al. 2019). 
 
2.2. Syndromic immunodeficiency 
 
Some PID combine abnormalities of the immune system with defects in other organ systems 
and are thus designated "syndromic PID" (Bousfiha, et al. 2018, Kersseboom, et al. 2011). The 
associated features in syndromic PID include short stature, facial dysmorphism, neurologic 
abnormalities and skin disorders (Bousfiha, et al. 2018, Kersseboom, et al. 2011). 
Syndromic PID with short-stature can be further subdivided according to the presence or 
absence of skeletal dysplasia. The examples of syndromic PID with growth failure and no 
skeletal dysplasia are, among others, DNA repair defects like Nijmegen breakage syndrome, 
Bloom syndrome, DNA ligase IV syndrome, DNA ligase 1 deficiency and cernunnos deficiency 
(Bousfiha, et al. 2018, Kersseboom, et al. 2011, Maffucci, et al. 2018). 
PID associated with skeletal dysplasia include 1) cartilage-hair hypoplasia (MIM # 250250), 2) 
Schimke immuno-osseous dysplasia (MIM # 242900) (Schimke, et al. 1974), 3) Roifman 
syndrome (MIM # 616651) (Roifman 1999), 4) spondyloenchondrodysplasia with immune 
dysregulation (MIM # 607944) (Roifman and Melamed 2003), 5) immunodeficiency-23 (MIM 
# 615816) (Stray-Pedersen, et al. 2014), and 6) immunoskeletal dysplasia with 
14 
 
neurodevelopmental abnormalities (MIM # 617425) (Oud, et al. 2017). The underlying 
genetic defect, the type of skeletal dysplasia and immunodeficiency, and other associated 
features are distinct for each of these diseases (Table 1) (Baradaran-Heravi, et al. 2008, Briggs, 
et al. 2016, Dinur Schejter, et al. 2017, Guo, et al. 2017, Lipska-Zietkiewicz, et al. 2017, 
Notarangelo 2017, Pacheco-Cuellar, et al. 2017, Stray-Pedersen, et al. 2014). 
 
Table 1. Primary immunodeficiency disorders associated with skeletal dysplasia.  
Disease Genetic 
defect 
Skeletal features Immunodeficiency Other features 
CHH RMRP Metaphyseal 
chondrodysplasia 
Combined Hair hypoplasia, anemia, increased 
incidence of malignancies and 
Hirschsprung disease 
SIOD SMARCAL1 Spondyloepiphyseal 
dysplasia 
Combined Glomerulopathy, abnormal skin 
pigmentation, dysmorphic features, 
cerebral ischemia, bone marrow 
hypoplasia 
Roifman 
syndrome 
RNU4ATAC Spondyloepiphyseal 
dysplasia 
Humoral Retinal dystrophy, developmental 
delay, dysmorphic features, 
autoimmunity 
SPENCDI ACP5 Spondylometaphyseal 
dysplasia 
Combined Autoimmunity, developmental 
delay, spasticity, intracranial 
calcifications 
IMD23 PGM3 Spondylometaphyseal 
dysplasia 
Combined Cardiovascular abnormalities, 
developmental delay, dysmorphic 
features 
ISDNA EXTL3 Spondyloepimetaphyseal 
dysplasia 
Combined Developmental delay, dysmorphic 
features, liver cysts 
CHH cartilage-hair hypoplasia, IMD23 immunodeficiency-23, ISDNA immunoskeletal dysplasia with 
neurodevelopmental abnormalities, SIOD Schimke immuno-osseous dysplasia, SPENCDI 
spondyloenchondrodysplasia with immune defect. 
 
2.3. Historical overview of cartilage-hair hypoplasia 
 
Maroteaux et al reported a specific form of metaphyseal dysplasia in 1963 (Maroteaux, et al. 
1963). Two years later, McKusick et al described a cohort of 77 Amish patients with a similar 
type of growth failure (McKusick, et al. 1965). These patients presented with short-limbed 
short stature at birth and fine, sparse and light-colored hair. Additional features in some 
subjects included malabsorption, congenital megacolon and fatal varicella. Short stature was 
the consequence of cartilage hypoplasia confined to the metaphyseal parts of the long bones. 
The frequency of this type of skeletal dysplasia in the Amish population was estimated to be 
1-2: 1,000 live births and the disease was named CHH. 
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In 1972, Perheentupa et al reported 21 patients with CHH from a single hospital in Finland, 
and this rare chondrodysplasia was then recognized to be overrepresented in the Finnish 
population (Perheentupa 1972). In 1990s Mäkitie et al described a large series of over 100 
patients with CHH from Finland, demonstrating the incidence of 1: 23,000 live births. In 
addition to the short stature, most patients showed defective immunity, and more than half 
had increased susceptibility to infections (Makitie 1992, Makitie and Kaitila 1993). The 
association of CHH with anemia, malignancies and Hirschsprung disease was described and 
confirmed by later studies (Makitie, et al. 2001, Makitie, et al. 1992, Taskinen, et al. 2008). 
In the 1970s, the laboratory features of immunodeficiency in CHH were reported in Amish 
and Finnish patients, highlighting lymphopenia, decreased numbers of B and/or T cells, 
impaired lymphocyte responses to mitogens and normal levels of serum immunoglobulins 
(Lux, et al. 1970, Ranki, et al. 1978, Virolainen, et al. 1978).  
The mechanisms of immunodeficiency in CHH were uncovered in 1980s by demonstrating an 
intrinsic proliferation defect in lymphocytes and impaired T cell function (Pierce, et al. 1983, 
Pierce and Polmar 1982). CHH was then considered a pure T cell-mediated immunodeficiency 
with unaffected humoral immunity. However, cellular and humoral immunity are closely 
linked, and abnormalities in T cell compartment almost always affect the performance of B 
cells (Figure 1) (Noelle and Snow 1991). Consistent with this concept, the impairment of 
humoral immunity was confirmed in patients with CHH in 2000 (Makitie, et al. 2000). 
 
Figure 1. A simplified graphic presentation of the interaction between humoral and cell-
mediated immunity. Upon antigenic stimulation, CD4+ T cells participate in the activation of 
cytotoxic CD8+ T cells and antibody-producing B cells. 
 
16 
 
The genetic defect behind CHH remained a mystery for years until, in 2001, Ridanpää et al 
reported mutations in RMRP as a cause of CHH (Ridanpaa, et al. 2001). RMRP encodes the 
untranslated RNA component of the mitochondrial RNA-processing endoribonuclease which 
modulates multiple cellular functions, and this discovery opened the path for studies on CHH 
pathogenesis.  
 
2.4. Pathogenesis of cartilage-hair hypoplasia 
2.4.1. Mutations in the RMRP gene 
 
The carrier frequency of CHH is Finland is approximately 1: 76, and all previously described 
Finnish patients with CHH share the same variant in RMRP, either in homozygous or 
compound heterozygous state (Makitie 1992). This ancient founder mutation n.71A>G (NCBI 
reference sequence: NR_003051.3, previously known as n.70A>G) is also the disease-causing 
variant in the Amish patients with CHH (Ridanpaa, et al. 2003, Ridanpaa, et al. 2002). Over 70 
other RMRP variants have been described in subjects with CHH (Martin and Li 2007, 
Mattijssen, et al. 2010). Some mutations are situated in the promoter region and can affect 
the level of RMRP transcription, while others are located in all domains of the transcribed 
region, either affecting highly conserved nucleotides or altering the secondary structure of 
RMRP (Figure 2) (Thiel, et al. 2007).  
 
Figure 2. The secondary structure of RMRP. The position of the most common disease-causing 
variant worldwide, n.71A>G, is marked by red circle. Modified with permission from fRNAdb 
© Toutai Mituyama (National Institute of Advanced Industrial Science and Technology) 
licensed under CC Attribution-Share Alike 4.0 International. 
 
17 
 
In addition to CHH, two other types of skeletal dysplasia are linked to RMRP, anauxetic 
dysplasia-1 (MIM # 607095), and metaphyseal dysplasia without hypotrichosis (MIM # 
250460). Anauxetic dysplasia differs from CHH by an extremely severe short stature, the 
involvement of vertebrae, pelvis and femoral epiphyses, and the absence of other extra-
skeletal manifestations except for mild mental retardation (Horn, et al. 2001, Menger, et al. 
1996, Thiel, et al. 2005). Metaphyseal dysplasia without hypotrichosis refers to an isolated 
chondrodysplasia with no extra-skeletal features (Bonafe, et al. 2002, Verloes, et al. 1990). 
 
2.4.2. Cellular consequences of the RMRP mutations 
 
RMRP is the RNA component of the mitochondrial RNA-processing ribonuclease, forming this 
universal eukaryotic enzyme complex together with ten protein subunits (Figure 3) (Esakova 
and Krasilnikov 2010). Mutations in POP1 gene encoding the POP1 subunit underlie anauxetic 
dysplasia-2 (MIM # 602486) (Barraza-Garcia, et al. 2017, Elalaoui, et al. 2016, Glazov, et al. 
2011), highlighting the crucial importance of RNase MRP in skeletal development. 
 
Figure 3. The structure of human mitochondrial RNA-processing ribonuclease, showing the 
10 protein subunits and the one RNA component RMRP. Reproduced with permission from 
the RNApathways DB (http://www.genesilico.pl/rnapathwaysdb) (Milanowska, et al. 2013). 
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The molecular mechanisms contributing to immunodeficiency in CHH still remain 
incompletely understood. At the cellular level, the consequences of RMRP mutations in 
humans include impaired rRNA and mRNA processing which results in prolonged cell cycle 
(Thiel, et al. 2005). The degree of the RNA degradation defect has been reported to correlate 
with the severity of clinical features (Thiel, et al. 2007). rRNA and mRNA cleavage activity 
correlate with the degree of bone dysplasia and immunodeficiency, respectively (Thiel, et al. 
2007). In addition, RMRP is the source of small RNAs that have regulating activity on genes 
associated with cell proliferation and differentiation (Rogler, et al. 2014). 
The cellular basis of immunodeficiency in CHH includes reduced growth of granulocyte-
macrophage progenitors from the bone marrow (Juvonen, et al. 1995), defective proliferation 
and increased apoptosis of the peripheral T cells (de la Fuente, et al. 2011), as well as 
decreased thymopoiesis and thymic dysplasia (Kavadas, et al. 2008). 
 
2.4.3. Diseases of the non-coding RNAs 
Only a few human diseases are caused by mutations in non-coding RNAs. These include CHH 
(RMRP, MIM # 157660), Roifman syndrome, Lowry-Wood syndrome and microcephalic 
osteodysplastic primordial dwarfism, type 1 (RNU4ATAC, MIM # 601428), and dyskeratosis 
congenita (TERC, MIM # 602322). While straightforward mechanisms explain clinical 
consequences of mutations in RNU4ATAC and TERC, this is not the case with RMRP.  
RNU4ATAC mutations impair minor intron splicing, which affects about 800 genes associated 
with DNA repair, RNA processing and cell cycle progression (Merico, et al. 2015). Interestingly, 
in patients with RNU4ATAC mutations, some clinical manifestations overlap with those in 
CHH. Growth failure, skeletal dysplasia and immunodeficiency characterize both, Roifman 
syndrome and CHH. However, patients with Roifman syndrome also present with retinal 
dystrophy and cognitive delay, both absent in CHH, and their skeletal changes consist of 
spondyloepiphyseal dysplasia compared to metaphyseal chondrodysplasia of CHH (Table 1) 
(Merico, et al. 2015). In addition, the immunodeficiency in Roifman syndrome arises from 
decreased numbers of B cells and hypogammaglobulinemia, leaving T cells unaffected 
(Heremans, et al. 2018). This contrasts the combined immunodeficiency in CHH (Table 1). In 
microcephalic osteodysplastic primordial dwarfism, a striking similarity with CHH is the hair 
hypoplasia, as well as metaphyseal skeletal changes. Severe microcephaly, brain 
abnormalities, epilepsy, neuroendocrine dysfunction and facial dysmorphism distinguish 
microcephalic osteodysplastic primordial dwarfism from CHH (Kroigard, et al. 2016, Merico, 
et al. 2015). Lowry-Wood syndrome is an allelic condition similar to Roifman syndrome, but 
less severe. It is characterized by multiple epiphyseal dysplasia without spinal involvement, 
distinct from Roifman syndrome, microcephalic osteodysplastic primordial dwarfism and CHH 
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(Farach, et al. 2018). Interestingly, the characteristic feature of limited elbow extension in 
CHH has been also reported in individuals with Lowry-Wood syndrome (Shelihan, et al. 2018). 
Patients with dyskeratosis congenita present with impaired skin pigmentation, mucosal and 
nail abnormalities, but also share some clinical manifestations with CHH, such as growth 
failure, immunodeficiency, anemia and increased incidence of malignancies (Nelson and 
Bertuch 2012, Savage 1993). Dyskeratosis congenita is a classic disorder of telomere biology, 
demonstrating the consequences of defective telomerase maintenance. TERC mutations 
affect telomerase activity leading to shorter telomeres (Vulliamy, et al. 2001). Telomeres are 
the end-fragments of human chromosomes that shorten with every cell division and are then 
repaired by telomerase (Harley, et al. 1990, Morin 1989). The telomerase complex consists 
of an RNA component TERC, a catalytic reverse transcriptase subunit TERT and associated 
proteins (Bertuch 2016). RMRP can bind TERT to form a distinct ribonucleoprotein complex 
that can produce double-stranded RNAs and regulate RMRP expression (Maida, et al. 2009). 
The impact of this RMRP-TERT interaction on telomeres in CHH has not been studied 
previously. 
 
2.5. Skeletal features of cartilage-hair hypoplasia 
 
The hypoplastic cartilage tissue confined mostly to the metaphyseal regions of long bones 
underlies the characteristic dysplastic skeletal phenotype in subjects with CHH (McKusick, et 
al. 1965). The onset of growth failure is prenatal and typical features of chondrodysplasia can 
be seen at birth in the majority of patients (Makitie, et al. 1992, McKusick, et al. 1965). The 
limbs are short, show signs of ligamentous laxity but limited elbow extension (Makitie and 
Kaitila 1993, McKusick, et al. 1965). Fingers and toes are short and flexible. Other 
manifestations include chest deformity, varus deformity of the lower extremities, increased 
lumbar lordosis and occasionally scoliosis (Makitie and Kaitila 1993, McKusick, et al. 1965).  
Radiologic signs assisting the diagnosis are typically present before the closure of the 
epiphyses and are thus absent in adulthood (McKusick, et al. 1965). The classic appearance 
of the metaphyses of the long bones is seen most clearly in the knee and include flaring, 
scalloping, irregularity, sclerosis, fragmentation and cystic changes (Figure 4) (McKusick, et 
al. 1965, Riley, et al. 2015). 
Birth length is subnormal in 70% of patients (Makitie and Kaitila 1993) and growth failure is 
progressive, especially during the first year of life and during puberty (Makitie, et al. 1992). 
The median adult height is 131 cm for males and 123 cm for females (Makitie, et al. 1992). 
Importantly, patients with CHH can present with normal height and no clinical or radiological 
signs of skeletal dysplasia (Kavadas, et al. 2008, Klemetti, et al. 2017). 
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Figure 4. Radiographs of patients with cartilage-hair hypoplasia at 4-6 years of age 
demonstrating the characteristic dysplastic appearance of the long bones with decreased 
length and widened and irregular metaphyses especially in the distal femur and proximal tibia 
(A, D), but also in the proximal femur (B), distal radius and metacarpals (C). The hand 
radiograph shows short tubular bones (C). 
 
 
 
2.6. Extra-skeletal features of cartilage-hair hypoplasia 
 
2.6.1. Infections 
 
CHH patients with symptomatic immunodeficiency typically suffer from recurrent upper and 
lower respiratory tract infections (RTI), including otitis media, sinusitis and pneumonia (Table 
2), caused by common pathogens like Haemophilus influenzae, Moraxella catarrhalis and 
Streptococcus pneumoniae (Bailly-Botuha, et al. 2008, Horn, et al. 2010). This pattern of 
infections apparently resembles humoral immunodeficiency, and a case of CHH with fatal 
enteroviral meningoencephalitis illustrates the severity of B cell dysfunction (Vatanavicharn, 
et al. 2010). 
However, some patients with CHH manifest symptoms of predominantly T cell impairment 
and severe combined immunodeficiency (SCID) phenotype (Roifman, et al. 2006). They 
acquire opportunistic infections with Pneumocystis jiroveci, Aspergillus spp, herpes viruses 
and other typical SCID pathogens (Table 2). Interestingly, apart from severe varicella, 
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opportunistic infections have only rarely been described in Finnish patients with CHH 
compared to other cohorts (Makitie, et al. 2001). 
Infections, mostly pneumonia and sepsis, are the main cause of death in Finnish children with 
CHH (Makitie and Kaitila 1993, Makitie, et al. 2001). However, not all patients suffer from 
recurrent or severe infections, despite obvious laboratory evidence for impaired immunity, 
including decreased CD3+, CD4+ and CD8+ T cells, CD19+ B cells, and recent thymic emigrants, 
as well as abnormal lymphocyte proliferation responses (de la Fuente, et al. 2011, Makitie 
and Kaitila 1993). In various cohorts, the prevalence of increased susceptibility to infections 
ranges from 11% to 100%, being most commonly reported at around 60% (Table 2). 
Several infection-related issues remain insufficiently explored in CHH, including the important 
question of whether the pattern of infections in childhood can predict clinical course and 
guide management decisions. In addition, it is unknown, whether recurrent RTI in childhood 
correlate with the development of chronic lung disease and bronchiectasis. 
 
2.6.2. Lung disease 
 
Bronchiectasis is the permanent dilatation of the airway resulting from chronic inflammation 
and infection, and thus is an expected complication in patients suffering from recurrent RTI 
(Flume, et al. 2018). The prevalence of bronchiectasis in large PID cohorts ranges from 9% to 
14% (Owayed and Al-Herz 2016, Rezaei, et al. 2006), and among various PID, patients with 
common variable immunodeficiency demonstrate the highest prevalence of bronchiectasis 
(57-70%) (Reisi, et al. 2017, Thickett, et al. 2002). In subjects with PID, low IgA is an 
independent risk factor for the development of bronchiectasis (Quinti, et al. 2011). 
Patients with CHH can present with a range of pulmonary problems, including asthma, viral, 
bacterial and fungal infections, interstitial lung disease and bronchiectasis (Bordon, et al. 
2010, de la Fuente, et al. 2011, Rider, et al. 2009). Bronchiectasis has been reported in 
children with CHH as young as 2.5 years, mostly in severe cases requiring HSCT (Bordon, et 
al. 2010, Moshous, et al. 2011). The high prevalence of bronchiectasis (52%) has been 
demonstrated in a retrospective cohort of 15 subjects with CHH and chronic respiratory 
symptoms (Toiviainen-Salo, et al. 2008). In this report, one patient required a lobectomy, and 
another died of pneumonia, underscoring the clinical significance of bronchiectasis. No 
clinical or laboratory features differed in patients with and without bronchiectasis, except for 
the absence of lymphopenia in the bronchiectasis group. Importantly, of the eight patients 
with bronchiectasis, only two demonstrated low IgG levels.  
Plain chest radiographs are usually insufficient to diagnose bronchiectasis or interstitial lung 
changes, and therefore, high-resolution computed tomography (HRCT) should be performed 
if these conditions are suspected (Smevik 2000). However, radiation exposure is a major 
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concern in patients with PID, adding to the increased risk of cancer. Lung magnetic resonance 
imaging (MRI) could be a promising alternative as it has demonstrated a sufficient correlation 
with CT in patients with cystic fibrosis, primary ciliary dyskinesia and PID (Milito, et al. 2015, 
Montella, et al. 2012, Puderbach, et al. 2007, Sileo, et al. 2014). However, with the current 
techniques available, the sensitivity of MRI may be insufficient to identify subtle changes, 
especially in small peripheral bronchi (Biederer, et al. 2012).  
Pulmonary changes in patients with CHH have not been examined systematically, and the 
role of lung MRI in assessing their lung pathology is unclear. The prevalence of bronchiectasis 
in clinically unselected patients with CHH and risk factors for the development of 
bronchiectasis remain unknown. Early recognition of bronchiectasis is of critical importance 
as these patients may develop rapid fatal infections (Horn, et al. 2010) and may require 
antimicrobial prophylaxis or immunoglobulin replacement therapy (IGRT) to combat 
progressive lung damage. 
 
2.6.3. Malignancies 
 
Patients with PID are more susceptible to malignancies, mostly non-Hodgkin’s lymphoma 
(Mayor, et al. 2018, Mortaz, et al. 2016). Patients with CHH are not an exception, 
demonstrating a sevenfold risk of cancer, primarily non-Hodgkin’s lymphoma (standardized 
incidence ratio (SIR) 90) and basal cell carcinoma (SIR 35) (Eisner and Russell 2006, Makitie, 
et al. 1999, Taskinen, et al. 2008).  
Non-Hodgkin’s lymphoma is a disease of young adults with CHH, given the SIR of 130 in the 
age group of 15-29 years (Taskinen, et al. 2008). It carries a poor prognosis in CHH cohort 
with median survival time of 6 months after the diagnosis (Taskinen, et al. 2008), and is the 
major cause of death in adults with CHH (Makitie, et al. 2001). This is similar to patients with 
other PID, who develop malignancies and have shorter survival compared with general 
population, as well as show high rates of relapse and secondary malignancy (Attarbaschi, et 
al. 2016). HSCT is considered a feasible therapeutic option in these individuals (Attarbaschi, 
et al. 2016, Wolska-Kusnierz, et al. 2015). 
The pathogenesis of malignancy in CHH is incompletely understood and probably combines 
several pathways. Lymphoproliferative disorders in patients with CHH can be Epstein-Barr 
virus-driven in some (McCann, et al. 2014, Sathishkumar, et al. 2018, Taskinen, et al. 2013), 
but not all cases (Nguyen, et al. 2018). While Epstein-Barr virus induces lymphoma in patients 
with Wisckott-Aldrich syndrome, most cases of lymphoma in subjects with common variable 
immunodeficiency are Epstein-Barr virus-negative (Mortaz, et al. 2016). Therefore, not only 
impaired viral suppression, but other mechanisms, such as chromosomal instability, may play 
a role (Hauck, et al. 2018, Verhoeven, et al. 2018). 
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2.6.4. Autoimmune diseases 
 
Autoimmune phenomena indicate immune dysregulation, and are, therefore, important 
signs of PID. Several reports describe patients with CHH and autoimmune diseases, such as 
enteropathy, hemolytic anemia, hypoparathyroidism, hypo- or hyperthyroidism, juvenile 
rheumatoid arthritis and neutropenia (Bacchetta, et al. 2009, Bonafe, et al. 2005, Bordon, et 
al. 2010, Rider, et al. 2009). Recently, a prevalence of 11% has been demonstrated for clinical 
autoimmunity in Finnish patients with CHH (Vakkilainen, et al. 2018). Despite frequent serum 
positivity for autoantibodies in individuals with CHH, no correlation with clinical symptoms 
has been observed (Biggs, et al. 2017, Vakkilainen, et al. 2018). 
 
2.6.5. Laboratory features of immunodeficiency in cartilage-hair hypoplasia 
 
Blood immunologic parameters in patients with CHH are highly variable, demonstrating no or 
mild abnormalities or severe impairment of both, cellular and humoral immunity (Table 2). 
The most consistent feature seen in the majority of patients (69-100%) is the decreased 
lymphocyte proliferation in response to mitogens (phytohemagglutinin). Also, in two series 
where T cell excision circles and recent thymic emigrants had been measured, they were low 
or absent in all tested samples. Many patients (36-94%) are lymphopenic, mostly due to the 
decreased numbers of T lymphocytes, especially CD4+ cells. CD16/56+ cell counts are usually 
normal but can be both elevated or decreased in some patients. The numbers of B cells are 
low in 9-75% of CHH cases, but hypogammaglobulinemia is infrequent. Instead, elevated IgG 
levels have been reported in 17-64% of patients. 
Neutropenia has been described in 6-27% of patients with CHH and may contribute to the 
increased susceptibility to infections (Ammann, et al. 2004, Makitie and Kaitila 1993, Makitie, 
et al. 1998). Up to 79% of children with CHH manifest anemia, often megaloblastic, which 
usually is mild and resolves spontaneously (Kainulainen, et al. 2014, Makitie and Kaitila 1993). 
However, in approximately 6% of patients, anemia is severe and transfusion-dependent 
(Taskinen, et al. 2013). 
To further complicate immunological evaluation, laboratory parameters in patients with CHH 
may fluctuate with time. Lymphopenia can be absent at presentation and develop later, 
lymphocyte proliferative responses can improve or worsen, and IgG levels can be decreased 
during infancy and then normalize, while IgM can be undetectable and then reappear 
(Kainulainen, et al. 2014, Kavadas, et al. 2008). 
While immunoglobulin levels, lymphocyte proliferation responses and the numbers of CD3+, 
CD4+ and CD8+ T cells, CD19+ B cells and CD16/56+ NK cells have been studied previously in 
most of the published CHH case series (Table 2), some other immunologic parameters have 
been rarely or never reported. Paucity of data exists regarding T and B cell subpopulations 
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and specific antibody responses in individuals with CHH (de la Fuente, et al. 2011, 
Kainulainen, et al. 2014). Furthermore, previous studies have included mostly pediatric 
patients, and data on the immune function in adults with CHH remain scarce. 
The clinical importance of impaired lymphocyte proliferative responses in subjects with CHH 
remain unclear.  Responses to phytohemagglutinin are better in some patients with milder 
clinical course, including those with less infections (de la Fuente, et al. 2011, Kavadas, et al. 
2008). In other reports, proliferative responses do not correlate with susceptibility to 
infections (Makitie and Kaitila 1993, Makitie, et al. 1998, Rider, et al. 2009). In CHH patients 
with more frequent RTI, both lower and higher absolute lymphocyte counts have been 
reported (Makitie, et al. 1998, Rider, et al. 2009), and, paradoxically, higher T cell and CD4+ 
cell counts and higher IgG levels (Makitie, et al. 1998, Makitie, et al. 2000). Two patients with 
CHH and CID necessitating HSCT showed elevated CD16/56+ counts, low IgG and 
undetectable IgA in the first 2 years of life, distinguishing them from the other 23 patients in 
the studied cohort (Rider, et al. 2009), but these correlations have not been confirmed in 
other studies. Altogether, previous reports provide ambivalent correlations of laboratory 
parameters with clinical course. 
 
2.7. Variability of manifestations 
 
The variability of clinical features in CHH has been well described, even in patients with 
identical RMRP mutations and within families (Kavadas, et al. 2008, Makitie and Kaitila 1993, 
Rider, et al. 2009, van der Burgt, et al. 1991). All previously reported Finnish patients with 
CHH were either homozygous or heterozygous for the most prevalent RMRP mutation 
n.71A>G, and therefore, phenotype variations are considered to be independent of the 
genotype. Polymorphisms in RMRP gene and non-allelic modifiers have been suggested as 
possible mechanisms (Notarangelo, et al. 2008, Thiel, et al. 2007). Previous studies have failed 
to explain the heterogeneity of symptoms or provide prognostic factors for the development 
of severe immunodeficiency or malignancies.  
The degree of immunodeficiency in CHH ranges from completely asymptomatic to severe 
combined immunodeficiency necessitating HSCT. Some patients present with recurrent or 
severe infections in the first year of life, while others develop late-onset immunodeficiency 
as adults (Horn, et al. 2010, Rider, et al. 2009). Such a diversity of clinical manifestations 
complicates the management of CHH on the individual level. While HSCT is the only life-saving 
option for severe cases, the optimal management of other patients remains uncertain and 
data on clinical and laboratory factors associated with prognosis are urgently needed.  
 
25 
 
Table 2. Infections and laboratory features in patients with cartilage-hair hypoplasia. 
Study N Age of 
pt, yrs 
Definition of increased 
susceptibility to infections 
Prevalence of 
increased 
susceptibility 
to infections, 
N (%) 
Types of 
infections 
Immunoglobulin levels, 
N (%) 
Cell counts, N (%) Abnormal 
lymphocyte 
proliferative 
responses to 
PHA, N (%) 
Makitie and 
Kaitila (1993) 
108 0.8 – 
52 
>6 uncomplicated URTI or 
≥3 protracted purulent inf 
such as OM or Sin in the 
preceding yr 
58/103 (56) OM, Pn, 
sepsis, 
severe 
varicella, 
Sin, URTI 
NA Ly ↓ 51/79 (65) 
Neutropenia 21/79 (27) 
53/60 (88) 
Makitie, et al. 
(1998) 
35 0.1 – 
55.5 
>6 uncomplicated URTI or 
≥3 protracted purulent inf 
such as OM, Sin or Pn per 
yr 
11/35 (11) OM, Pn, 
Sin, URTI 
Normal 16/16 (100) Ly ↓ 12/33 (36) 
Neutropenia 2/33 (6) 
CD4+ ↓ 17/30 (57) 
CD8+ ↓ 8/30 (27) ↑ 1/30 (3) 
CD19+ ↓ 2/23 (9) ↑ 2/23 (9) 
22/32 (69) 
Makitie, et al. 
(2000) 
20 1.7 – 
16.7 
>6 uncomplicated URTI or 
≥3 protracted purulent inf 
such as OM, Sin or Pn in 
the preceding yr 
10/20 (50) RTI IgG ↓ 0/20 (0)  
IgG ↑ 5/20 (25) 
IgM normal 20/20 (100) 
IgA deficiency 2/20 (10)  
NA NA 
Guggenheim, 
et al. (2006) 
3 6 – 21 Omenn syndrome 
described in 2 pts 
2/3 (67) Pn (PJ), 
thrush 
IgG ↓ 1/3 (33) 
IgM ↓ 1/3 (33) 
IgA deficiency 3/3 (100) 
CD3+ ↓ 3/3 (100) 
CD4+ ↓ 3/3 (100) 
CD8+ ↓ 3/3 (100) 
NK ↓ 1/3 (33) 
3/3 (100) 
Hermanns, et 
al. (2006) 
27 0.6 – 
32 
Inf incidence significantly 
above average in age-
matched controls 
12/22 (55) RTI or 
other 
Ig-s ↓ 2/5 (40) CD3+ ↓ 6/9 (67) 2/2 (100) 
Adeno adenovirus, bact bacterial, CD cluster of differentiation, CD19+ B cells, CD3+ T cells, CD4+ helper T cells, CD8+ effector T cells, CMV cytomegalovirus, 
EBV Epstein-Barr virus, EBV-LP EBV-related lymphoproliferation, HHV-6 human herpes virus 6, HSCT hematopoietic stem cell transplantation, HSV herpes 
simplex virus, Ig immunoglobulin, inf infection, Ly lymphocytes, N number of patients, NA not available, NK natural killer cells, OM otitis media, PHA 
phytohemagglutinin, PJ Pneumocystis jiroveci, Pn pneumonia, pt patients, Sin sinusitis, TREC T cell receptor excision circles, URTI upper respiratory tract 
infection, yr year, ↓ decreased, ↑ increased.  
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Table 2 (continued). Infections and laboratory features in patients with cartilage-hair hypoplasia. 
Study N Age of 
pt, yrs 
Definition of 
increased 
susceptibility to 
infections 
Prevalence 
of increased 
susceptibility 
to infections, 
N (%) 
Types of infections Immunoglobulin levels, 
N (%) 
Cell counts and 
TREC, N (%) 
Abnormal 
lymphocyte 
proliferative 
responses to 
PHA, N (%) 
Kavadas, 
et al. 
(2008) 
12 0.2-6, 
44 
Inf suggestive of 
immune deficiency 
8/12 (67) OM, Pn (Aspergillus, CMV, PJ), thrush IgG ↓ 3/11 (27)  
IgG ↑ 7/11 (64) 
IgM ↓ 1/11 (9) 
IgA deficiency 3/11 (27) 
 
Ly ↓ 10/12 (83) 
CD3+ ↓ 12/12 (100) 
CD8+ ↓ 12/12 (100) 
CD4+ ↓ 11/12 (92) 
CD19+ ↓ 6/12 (50) 
NK ↓ 2/12 (17)  
TREC ↓ 4/5 (80) 
11/11 (100) 
Rider, et 
al. (2009) 
25 0.8-21 Life-threatening inf 
prior to age 2 yrs or 
>2 bact inf / yr during 
the first 2 yrs of life 
8/25 (32) Disseminated HSV, parvovirus; 
meningitis (Haemophilus influenzae); 
OM; Pn (bact, CMV); sepsis; Sin; thrush 
IgG ↓ or ↑ in some 
IgM ↓ in some 
IgA deficiency 3/25 (12)  
Ly ↓ in the majority In most 
Bordon, 
et al. 
(2010) 
16 0.7-19 All pts required HSCT 16/16 (100) Adeno enteritis and hepatitis; 
disseminated CMV, EBV, HSV; OM; Pn 
(bact, varicella-zoster virus); severe 
varicella 
IgG ↓ 5/16 (31) 
IgM ↓ 5/16 (31) 
IgA ↓ 8/16 (50) 
Ly ↓ 15/16 (94) 
CD3+ ↓ 15/16 (94) 
CD4+ ↓ 15/16 (94) 
CD8+ ↓ 15/16 (94) 
CD19+ ↓ 12/16 (75) 
NK ↓ 2/13 (15) 
14/15 (93) 
de la 
Fuente, et 
al. (2011) 
18 1-21 Severe and/or 
recurrent inf, not 
further defined 
11/18 (61) EBV-LP, molluscum, parvovirus, Pn 
(Aspergillus, CMV), sepsis, URTI 
Normal Ig-s 11/14 (79) CD3+ ↓ 10/18 (56) 
CD4+ ↓ 18/18 (100) 
CD8+ ↓ 13/18 (72) 
CD19+ ↓ 8/18 (44) 
RTE ↓ 18/18 (100) 
11/13 (85) 
Ip, et al. 
(2015) 
13 0-9 All pts required HSCT 13/13 (100) Disseminated adeno, CMV, EBV, HHV-6; 
EBV-LP; enteritis (adeno, HHV-6); OM; 
RTI; severe varicella 
IgG ↓ 4/12 (33)  
IgG ↑ 2/12 (17) 
IgA ↓ 7/12 (58)  
IgM ↓ 5/12 (42)  
CD4+ ↓ 13/13 (100) 
CD8+ ↓ 9/13 (69) 
CD19+ ↓ 5/13 (38) 
TREC ↓ 9/9 (100) 
9/11 (82) 
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3. AIMS OF THE STUDY 
Several aspects of CHH remain poorly explored, including the pathogenesis, lung disease, 
detailed characteristics of immunologic phenotype, correlations of clinical and laboratory 
features, disease course and prognosis, as well as factors associated with adverse outcomes. 
To address these questions, we recruited and carefully examined a large cohort of Finnish 
children and adults with CHH aiming for sufficient sample size, detailed and accurate data 
collection and long-term follow-up. 
 
The aims of this doctoral work were as follows: 
 
 
1. To further explore the molecular consequences of RMRP mutations and the pathogenesis 
of CHH by measuring relative telomere length in a large cohort of patients with CHH, their 
first-degree relatives and healthy controls, and by analyzing the correlation of telomere length 
with the clinical and laboratory manifestations of CHH. 
 
2. To further elucidate the immunologic features and determinants predicting clinical 
infections by studying infectious manifestations and performing a thorough immunologic 
characterization in a large group of children and adults with CHH. 
 
3. To examine the prevalence of bronchiectasis, as well as clinical and immunologic risk factors 
for the development of bronchiectasis in a random sample of patients with CHH and compare 
the performance of lung MRI and HRCT in the assessment of lung changes. 
 
4. To follow-up a large cohort of patients with CHH and analyze the clinical course and factors 
influencing survival and the development of malignancies. 
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4. PATIENTS AND METHODS 
 
4.1. Patients 
 
The protocol for all studies was approved by the Institutional Research Ethics Committee at 
Children’s Hospital, Helsinki University Hospital, Finland. All participants and/or their parents 
gave informed consent. 
We used the Finnish Chondrodysplasia Registry to invite Finnish patients with genetically 
confirmed CHH (Figure 5). Regardless of their medical history, all subjects who agreed to 
participate were included. For study I, patients’ first-degree relatives were contacted via the 
index persons. 
 
Figure 5. Number (N) of recruited patients with cartilage-hair hypoplasia (CHH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For study I, we used a control group of healthy RMRP mutation-negative individuals to 
compare the results of telomere measurements. We analyzed samples from 86 first-degree 
relatives of the patients, all unaffected, including 37 parents, 38 siblings and 11 children. 
Genetically, 74 of them were confirmed to be heterozygous carriers of RMRP mutations, 
while 12 lacked RMRP mutations and were included in the control group. Additionally, 
All known Finnish patients with CHH (N = 104-110) were invited to participate 
STUDY IV 
Recruited in 1985-1991 
N = 80 
STUDY II 
Recruited in 2011-2015 
N = 56 
(including 32 patients from Study IV) 
STUDY I 
Telomere length measured 
N = 48 
STUDY III 
Lung imaging performed 
N = 34 
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samples from participants of our previous studies involving healthy children and adults (n = 
94) were included as controls. Some statistical analyses implicated a case-control setting, for 
which age- and sex-matched healthy controls were identified for each patient or RMRP 
mutation carrier with age difference of no more than 12 months. 
For Study IV, we recruited all known Finnish patients with CHH in 1985-1991 and followed 
them up in 2011-2015 (Figure 6).  
 
Figure 6. Recruitment and follow-up of the patients for Study IV, and data availability.  
N = number of patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
All Finnish patients with cartilage-hair hypoplasia known in 1985-1991 
N = 104 
Attended the follow-
up in 2011-2015 
N = 32 
Alive but declined 
the follow-up 
N = 31 
Patients recruited in 1985-1991 
 
N = 80 
Deceased prior 
to 2011-2015 
N = 17 
Data from all registries available for all 
N = 80 
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4.2. Clinical data 
 
During 1985-1991 and 2011-2015, study participants visited Helsinki University Hospital. We 
performed a standard clinical examination, interviewed patients for medical history and 
retrieved additional information from hospital records. In 2011-2015, a structured 
questionnaire inquired about hospitalizations, medications, surgical procedures, previous 
radiologic investigations, infections and respiratory symptoms. In addition, we recorded 
factors potentially influencing telomere length, including the history of smoking, intake of 
hormonal or immunosuppressive medications and obesity (body mass index Z-score). Clinical 
information available on healthy controls in Study I consisted of data on age, sex, ethnic 
background (all Finnish) and overall health (all healthy). 
For all 80 patients from Study IV, we collected health information from the two Finnish 
National Medical Databases. Data from the Finnish National Care Registry for Health Care 
(Hilmo) covered the period from 1969 to 2016 and included data on inpatient health service 
providers, while the Finnish National Registry of Primary Health Care Visits (Avohilmo) 
covered outpatient health service provider data in 2011-2016. Information included dates of 
visits, diagnosed conditions, as well as diagnostic and therapeutic procedures. We then 
obtained all patients’ health records from all identified inpatient health service providers for 
further analysis. In addition, we collected data on malignancies from the Finnish Cancer 
Registry, covering time period from 1953 to 2016, as well as mortality data from the Cause-
of-death Registry of Statistics Finland for the period of 1971-2016. We analyzed the causes of 
death based on the registry data and also from the patient records. 
We classified patients as having mild (height above the 75th percentile for age and sex on the 
CHH growth curves), moderate (between 25th and 75th percentile) or severe (below the 25th 
percentile) growth failure in accordance with age- and sex-specific growth data for patients 
with CHH based on the latest available height measurement (Makitie, et al. 1998, Makitie, et 
al. 1992). We also used birth length standard deviation (SD) score to characterize the severity 
of growth failure (Pihkala, et al. 1989). Patients were considered to have contracted varicella 
zoster virus if they had a history of varicella or detectable serum antibodies to varicella zoster 
virus, and we used hospitalization as a marker of severe varicella. Other definitions used in 
the studies are listed in Table 3. 
Based on their clinical manifestations, patients were grouped as having: 1) no clinical 
symptoms of immunodeficiency, 2) clinical features of humoral immunodeficiency only and 
3) clinical features of CID. The categorization differed for Studies I-II and Study IV due to the 
different settings and the availability of considerable amount of additional data in Study IV 
(Table 3). In this thesis, the definitions used in Study IV were applied. 
For Study IV, we selected several primary outcomes: 1) mortality (assessed by evaluating 
deaths related to immunodeficiency, including death from infections, pulmonary diseases 
and malignancies), 2) the development of lymphoma and 3) the development of skin cancer. 
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Table 3. Terms and their definitions applied in the studies. 
 
Term Definition 
Children Individuals aged 0-18.0 years 
Adults Individuals aged over 18.0 years 
Chronic cough Ongoing daily cough lasting at least one year 
Recurrent pneumonia Two or more episodes within one year or three or more episodes during lifetime 
Recurrent otitis media 
and/or rhinosinusitis 
Three or more episodes within six months, four or more episodes within a year or 
at least ten episodes during lifetime 
Sepsis Compatible clinical signs presenting simultaneously with positive blood cultures 
Bacterial skin infections Impetigo, boils and/or cellulitis 
Viral skin infections Warts, molluscum contagiosum and/or recurrent mucocutaneous herpes simplex 
virus infections 
Refractory warts Skin and/or anogenital warts persisting for years and unresponsive to multiple 
therapies 
Mucocutaneous Candida 
infections 
Thrush beyond the first six months of life and esophagitis 
Opportunistic infections Refractory warts, recurrent mucocutaneous herpes simplex virus infections, 
mucocutaneous Candida infections and/or severe varicella 
Humoral 
immunodeficiency 
Study I, II Otitis media or rhinosinusitis requiring surgery, sepsis, pneumonia 
and/or bronchiectasis 
Study IV Recurrent respiratory tract infections and/or sepsis 
Combined 
immunodeficiency 
Study I, II Additional features of refractory warts, recurrent and/or severe 
herpes virus infections, malignancy and/or autoimmunity 
Study IV Additional features of autoimmunity and/or opportunistic infections 
 
 
4.3. Laboratory data  
 
To assess the immunologic phenotype, we obtained non-fasting blood tests from patients (n 
= 56) at the time of visits. In the majority of the patients (n = 48), as well as for their first-
degree relatives, we also collected blood samples for DNA extraction and relative telomere 
length (RTL) measurement, while previously available DNA samples were used for healthy 
controls. DNA extraction was performed using 5 Prime Archive Pure DNA Blood kit (5 Prime 
GmbH, Hilden; Germany). 
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We analyzed leukocytes, neutrophils, eosinophils and lymphocyte subsets with flow 
cytometry and compared the results with local laboratory reference values. Previously 
published reference data were applied for cell counts in children (Shearer, et al. 2003), for 
CD3/CD4/CD45RA/CD31+ cells (recent thymic emigrants) (Boldt, et al. 2014, Schatorje, et al. 
2012), for CD27+ (memory) B cells (Driessen, et al. 2011) and for other B and T cell 
subpopulations, including naive, activated and memory B and T cells, regulatory and double-
negative T cells, as well as transitional and marginal zone-like B cells and plasmablasts (Boldt, 
et al. 2014, Wehr, et al. 2008).  
We measured immunoglobulins and IgG subclasses as described previously (Makitie, et al. 
2000) and applied the available reference values for IgG subclasses (Vlug, et al. 1994). 
Antibodies to tetanus toxoid (n = 43) and varicella zoster virus were measured with enzyme 
immunoassay (Aalto, et al. 1998, Jaaskelainen, et al. 2014, Kristiansen, et al. 1997). 
Concentrations of tetanus antibodies higher than 0.1 IU/ml were considered protective. We 
excluded patients receiving IGRT at the time of the studies I-III (n = 4) from analysis of 
antibodies to vaccines, IgG and subclasses. 
In eight patients aged 23-67 years, we used fluoroimmunoassay to assess antibody responses 
to pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F after immunization with 
unconjugated 23-valent pneumococcal polysaccharide vaccine (Pneumovax®) from samples 
pre- and 3-8 weeks post-immunization (Timby, et al. 2015). We defined normal response as 
post-immunization antibody levels of ≥ 0.35 µg/ml and a fourfold rise in serotype-specific 
antibodies to ≥ 70% of serotypes (Sorensen and Leiva 2014). 
In Study IV we also evaluated laboratory data from the hospital records and applied the 
reference values of the laboratories where the samples were analyzed.  
 
4.3.1. RMRP gene sequencing  
 
For the majority of patients (51/56, 80/80), genetic data was readily available. In addition, we 
sequenced RMRP in all samples to confirm the genotype in patients from study I and to detect 
heterozygous mutations in the patients’ relatives and healthy controls. Primers for RMRP 
(GRCh37/hg19) were designed with Primer3 v.0.4.0 (http://frodo.wi.mit.edu/primer3/) tool, 
with a minimum of 60 bases of flanking regions adjacent to the coding region. PCR was 
amplified with DreamTaq (ThermoScientific, Waltham, MA, USA). DNA fragments were 
visualized on agarose gel with Midon Green Advanced DNA Stain (NIPPON Genetics, GmbH, 
Europe), purified with ExoSAP (USB, Cleveland, OH, USA) and labeled with BigDye Terminator 
v3.1 Cycle Sequencing kit (Applied Biosystems). Following bidirectional sequencing with an 
ABI3730 sequencer (Applied Biosystems), chromatograms were analyzed with Sequencher 
v5.0 (Gene Codes Corporation, Ann Arbor, MI, USA) using genomic NG_017041.1 and RNA 
reference sequence NR_003051.3.  
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4.3.2. Measurement of telomere length  
 
Telomere length was measured with quantitative-PCR method (Cawthon 2002, Degerman, et 
al. 2014). DNA was analyzed twice in triplicate wells in a separate Telomere (TEL) and a single 
copy gene (HBG) reaction using the ABI7900HT instrument (Applied Biosystems). TEL/HBG 
(T/S) values were calculated with the 2−ΔCt method, where ΔCt = average CtTEL - average 
CtHBG. RTL values were generated by dividing samples T/S value with the T/S value of a 
reference DNA of CCRF-CEM cell line, which was included in all runs. We categorized 
individuals as having short, average or long RTL for age based on the data from healthy 
controls. Subjects with RTL > 0.5 SD from the regression line for age vs RTL were considered 
to have long RTL, those with RTL < -0.5 SD – short RTL, and all the rest - average RTL. In further 
analysis, we used both, RTL itself and RTL categories. 
 
 
4.4. Imaging studies 
 
All patients from Study III (n = 34) underwent lung HRCT, and in 16 out of these 34 patients, 
lung MRI was performed on the same day. Two experienced radiologists who were blinded 
for the patients’ clinical data together analysed and scored all MRI and HRCT images. Scoring 
was performed using modified Helbich (Bhalla) system (Puderbach, et al. 2007); the final 
scores in each patient and study were reached by consensus. Nine parameters were evaluated 
with a maximum possible score of 27 points (Puderbach, et al. 2007). A cut-off value of ≥7 
points was chosen for the diagnosis of bronchiectasis.  
 
 
4.5. Statistical analyses 
 
Correlation of the tested laboratory parameters with clinical manifestations and primary 
outcomes were analyzed using the Fisher’s exact test, the Mann-Whitney or the Kruskall-
Wallis tests and regression analyses, as appropriate.  
We compared the performance of HRCT and MRI by calculating the Spearman’s rank 
correlation coefficient (rho). The latter parameter was also implicated to evaluate the 
influence of age on various laboratory parameters.  
For the calculation of standardized mortality ratios (SMR), we derived the expected numbers 
of deaths by multiplying person-years by the mortality rate in general population. SMR were 
then calculated as the proportion of the number of observed and expected deaths. SIR for 
malignancies were derived by dividing the number of observed malignancy cases by the 
number of expected malignancies in general population. We evaluated the significance of 
difference between SMRs in subgroups of patients by SMR/SMR ratio and its 95%CI. 
P values <0.05 were considered significant. Statistical analyses were accomplished with the 
IBM SPSS Statistics (versions 22-23). 
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5. RESULTS 
 
5.1. Patient characteristics 
 
5.1.1. General characteristics 
 
Table 4 compares general and clinical characteristics of the study patients. Number of female 
patients outweighed the number of males in all studies. Patients from all age groups, from 
childhood to adulthood, were included. In the RMRP genotyping, all patients were either 
homozygous for the most common CHH causing variant n.71A>G, or compound heterozygous 
for n.71A>G/g.262G>T or n.71A>G and a 10-nucleotide duplication at position -13 
(TACTCTGTGA). In Study IV, the surviving patients were followed-up for the median of 29.2 
years (range 25.6 – 31.0 years). 
 
Table 4. Characteristics of the study patients. 
 Study I Study II Study III Study IV 
Focus of the study Telomere 
length 
Immunologic 
characteristics 
Lung disease Disease course 
and risk factors 
General characteristics of the patients 
Number of patients 
Number of males / females 
Median age at recruitment (range), years 
Homo-/heterozygous for RMRP n.71A>G variants 
48 
17 / 31 
38 (6 – 70) 
75% / 25% 
56 
19 / 37 
34 (0.7 – 68) 
77% / 33% 
34 
6 / 28 
39 (13 – 68) 
85% / 15% 
80 
35 / 45 
15 (0.0 – 50) 
78% / 22% 
Prevalence of clinical features during lifetime, number (%) 
Otitis media 
Rhinosinusitis 
Pneumonia 
Sepsis 
Warts 
Mucocutaneous herpes simplex virus infections 
Varicella requiring hospitalization 
Allergic rhinitis 
Physician-diagnosed asthma 
Malignancies 
34/47 (72) 
27/47 (57) 
10/47 (19) 
NA 
15/47 (32) 
NA 
5/34 (15) 
NA 
NA 
9/47 (19) 
41/56 (73) 
33/56 (59) 
11/56 (20) 
3/56 (5) 
19/56 (34) 
2/56 (4) 
5/42 (12) 
23/56 (41) 
NA 
9/56 (16) 
25/34 (74) 
24/34 (71) 
8/34 (24) 
NA 
NA 
NA 
NA 
15/34 (44) 
10/34 (29) 
NA 
58/80 (73) 
48/80 (60) 
32/80 (40) 
8/80 (10) 
26/80 (33) 
2/80 (3) 
4/66 (6) 
NA 
17/80 (21) 
21/80 (31) 
NA not available, RMRP RNA component of the mitochondrial RNA-processing endoribonuclease 
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5.1.2. Infectious manifestations (Study IV) 
 
The most common infections occurring in the study patients were RTI, characteristically ear 
infections in childhood and rhinosinusitis in teenagers and adults (Table 4). Although the 
prevalence of pneumonia, rhinosinusitis and otitis media was significant in the study cohort 
(40%, 60% and 73% respectively), only 38% of patients had recurrences of these infections.  
Common pathogens had been detected in the aspirates from middle ear and paranasal 
sinuses in patients with recurrent otitis media and rhinosinusitis respectively: Haemophilus 
influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Streptococcus pneumoniae, 
Streptococcus pyogenes and Staphylococcus aureus.  
Other described infections included sepsis, skin infections and severe varicella (Table 4). 
Sepsis was more common in children (n = 7) than in adults (n = 2). Sepsis episodes in three 
children and both cases of sepsis in adults were associated with central venous catheter. 
Organisms causing sepsis included Candida spp, Enterococcus spp, Haemophilus influenzae, 
Klebsiella pneumonia, Lactobacillus rhamnosus and Staphylococcus spp. Viral skin infections, 
mostly warts, were more prevalent that bacterial skin infections (30/80, 38% vs 18/80, 23%). 
A significant proportion of patients with warts had refractory disease (9/22, 41%), all in 
adulthood. 
Opportunistic infections were diagnosed in 20% of the patients and included mucocutaneous 
Candida spp infections, refractory warts and recurrent mucocutaneous herpes simplex virus 
infections, as well as severe varicella. 
 
5.2. Clinical patterns and the course of immunodeficiency (Study IV) 
 
Several patterns of the disease course were recognized. A large group of patients (46/80, 57%) 
had clinically asymptomatic immunodeficiency. However, eight of these 46 individuals 
developed non-skin malignancy of which five died. Clinical humoral immunodeficiency was 
demonstrated in 15 patients (15/80, 19%) and another 19 subjects developed clinical features 
of CID (19/80, 24%). 
Importantly, clinical manifestations of immunodeficiency progressed in a significant 
proportion of patients (17/79, 22%). Six asymptomatic children developed immunodeficiency 
in adulthood. Eleven children with humoral immunodeficiency progressed to CID as adults. 
Table 5 describes the course of the immunodeficiency and the outcomes. The 
immunodeficiency-related mortality in patients grouped by the type of clinical 
immunodeficiency in childhood is illustrated in Table 5. Children with clinical features of CID 
(n = 7) demonstrated the most severe disease course, with only one patient being alive and 
cancer-free at the end of the follow-up. Of the 52 asymptomatic children and of 20 subjects 
with symptoms of humoral immunodeficiency in childhood, only 34 and five, respectively, 
were alive and had not developed cancer nor CID. 
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Table 5. The course of clinical immunodeficiency (ID) during lifetime in 80 patients with 
cartilage-hair hypoplasia. Malignancies are described as the total number of diagnosed cases 
of non-skin cancers. 
Childhood Adulthood Mortality and the development of 
malignancies, [mean age at cancer diagnosis] 
No ID 52/80 (65%) No ID 46/52 (88%) Alive/Deceased 39 (85%) / 7 (15%) 
Cancer 9/46 (20%) [42 years] 
Humoral ID 5/52 (10%) Alive/Deceased 5 (100%) / 0 (0%) 
Combined ID 1/52 (2%) Alive/Deceased 0 (0%) / 1 (100%) 
Cancer 1/1 (100%) [69 years] 
Humoral ID 20/80 (25%)  
  1/20 deceased  
No ID 5/20 (25%) Alive/Deceased 4 (80%) / 1 (20%) 
Cancer 1/5 (20%) [26 years] 
Humoral ID 3/20 (15%) Alive/Deceased 2 (67%) / 1 (33%) 
Combined ID 11/20 (55%) Alive/Deceased 8 (73%) / 3 (27%) 
Cancer 2/11 (18%) [39 years] 
Combined ID 7/80 (9%) 
  1/7 deseased 
No ID 1/7 (14%) Alive/Deceased 1 (100%) / 0 (0%) 
Combined ID 5/7 (72%) Alive/Deceased 2 (40%) / 3 (60%) 
Cancer 4/5 (80%) [23 years] 
Insufficient data 1/80 (1%) Humoral ID 1/1 (100%) Alive/Deceased 0 (0%) / 1 (100%) 
 
 
5.3. Laboratory immunologic characteristics (Study II) 
 
Table 6 describes immunologic laboratory parameters in a cohort of patients with CHH. 
Lymphopenia was detected in 55% of the study subjects. Decreased B cell counts were 
reported more frequently than decreased T cell or NK cell counts (67% vs 45% vs 7%). IgG 
level was low in a single patient, aged 58 years, who suffered from recurrent rhinosinusitis 
only. Naive thymic CD3+CD4+CD45RA+CD31+ cells were low in 27/52 patients (52%). 
Abnormalities detected in other T cell subpopulations (in n = 11, Table 7) consisted of 1) 
decreased naive CD4+ and CD8+ cells; 2) increased activated CD4+ cells; 3) increased central 
memory CD4+ and effector memory CD8+ cells; 4) increased TCR-α/β+ and decreased TCR-
γ/δ+ cells. Regulatory T cells appeared normal in 10 out of 11 tested patients.  
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Table 6. Laboratory immunologic parameters in patients with cartilage-hair hypoplasia. Cell 
counts are reported as cells x109/l and immunoglobulin (Ig) levels as g/l.  
 
 Normal 
values* 
Number 
tested 
Median (range) Decreased in, 
number (%) 
Increased in, 
number (%) 
Leukocytes 3.4-8.2 56 5.65 (1.2-12.0) 7 (13) 7 (13) 
Neutrophils 1.5-6.7 56 3.68 (0.28-8.4) 4 (7) 5 (9) 
Lymphocytes 1.3-3.6 56 1.31 (0.26-3.84) 31 (55) 0 (0) 
  CD3+ 
  CD4+ 
  CD3+CD4+CD45RA+CD31+ 
  CD8+ 
  CD19+ 
  CD27+IgD+ 
  CD27+IgD- 
  CD16/56+ 
0.85-2.28 
0.458-1.406 
0.024-0.824 
0.24-0.98 
0.12-0.43 
0.009-0.088 
0.013-0.122 
0.08-0.57 
55 
55 
52 
55 
55 
51 
51 
55 
0.92 (0.16-4.45) 
0.55 (0.12-3.83) 
0.03 (0.00-0.56) 
0.28 (0.04-1.72) 
0.12 (0.00-1.29) 
0.008 (0.000-0.044) 
0.098 (0.000-0.064) 
0.19 (0.05-0.63) 
25 (45) 
24 (44) 
27 (52) 
25 (45) 
37 (67) 
29 (57) 
34 (67) 
4 (7) 
2 (4) 
0 (0) 
0 (0) 
2 (4) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
IgG 6.8-15.0 50 10.45 (4.20-15.90) 1 (2) 2 (4) 
  IgG1 4.9-11.4 50 8.25 (3.24-14.00) 1 (2) 0 (0) 
  IgG2 
  IgG3 
  IgG4 
1.50-6.40 
0.20-1.63 
0.08-1.40 
50 
50 
55 
1.89 (0.27-4.56) 
0.44 (0.07-1.20) 
0.09 (0.00-0.92) 
 13 (26) 
 8 (16) 
 23 (46) 
0 (0) 
0 (0) 
0 (0) 
IgA 0.52-4.84 55 1.83 (0.00-7.49)  2 (4) 3 (5) 
IgM 0.36-2.84 55 0.90 (0.20-3.06)  7 (13) 1 (2) 
* Normal values in adults. In children age-specific normative data were used. 
 
 
All 11 patients showed an increased proportion of activated CD21low, CD38low B cells (Table 
7). When absolute numbers of B cell subpopulations were assessed, 7/11 patients had low 
naive B cells and low transitional cells and 6/11 patients had low marginal-zone like B cells. 
CD27+ B cell counts were decreased in the majority of patients.  
Inadequate serotype-specific responses to unconjugated pneumococcal polysaccharide 
vaccine were observed in 7/8 patients who agreed to be immunized (Table 8), two of them 
showed clinical signs of humoral immunodeficiency and four of CID. Interestingly, none of the 
patients with specific antibody deficiency reported pneumonia, but all had a history of 
rhinosinusitis. Other clinical features of the seven subjects with specific antibody deficiency 
included otitis media (n = 5), warts (n = 3), malignancies (n = 3), severe varicella requiring 
hospitalization (n = 2) and recurrent herpes simplex virus infections (n = 1). Three out of 43 
subjects showed suboptimal antibody levels to tetanus toxoid. For two of them, the time of 
immunization, if any, was unknown. The remaining patient was re-immunized two years prior 
to the testing and he also had specific antibody deficiency. 
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Table 7. Subpopulations of B and T cells in patients with cartilage-hair hypoplasia. Local 
laboratory or previously published reference values were applied (Boldt, et al. 2014, Wehr, et 
al. 2008). 
 
Flow cytometry markers Cell group Units N tested Decreased 
in N (%) 
Normal in 
N (%) 
Increased 
in N (%) 
CD3+ T cells cells x109/l 12 6 (50) 5 (42) 1 (8) 
CD4-CD8- 
CD4+CD8+ 
TCR-α/β+ 
TCR-γ/δ+ 
CD4+CD25highCD127low 
DNT 
 
 
 
Regulatory 
% of CD3+ 
% of CD3+ 
% of CD3+ 
% of CD3+ 
% of CD3+ 
11 
11 
11 
11 
11 
0 (0) 
1 (9) 
1 (9) 
4 (36) 
1 (9) 
11 (100) 
9 (82) 
6 (55) 
6 (55) 
10 (91) 
0 (0) 
1 (9) 
4 (36) 
1 (9) 
0 (0) 
CD4+  cells x109/l 12 6 (50) 6 (50) 0 (0) 
CD45RA+CCR7+ 
HLA-DR+CD38- 
CD45RA-CCR7+ 
CD45RA-CCR7- 
CD45RA+CCR7- 
Naive CD4+ 
Activated CD4+ 
CD4+ TCM 
CD4+ TEM 
Effector memory CD4+ 
% of CD4+ 
% of CD4+ 
% of CD4+ 
% of CD4+ 
% of CD4+ 
11 
11 
11 
11 
11 
9 (82) 
0 (0) 
0 (0) 
1 (9) 
6 (55) 
2 (18) 
1 (9) 
0 (0) 
10 (91) 
5 (45) 
0 (0) 
10 (91) 
11 (100) 
0 (0) 
0 (0) 
CD8+  cells x109/l 12 10 (84) 1 (8) 1 (8) 
CD45RA+CCR7+ 
HLA-DR+CD38- 
CD45RA-CCR7+ 
CD45RA-CCR7- 
CD45RA+CCR7- 
Naive CD8+ 
Activated CD8+ 
CD8+ TCM 
CD8+ TEM 
Terminal effector CD8+ 
% of CD8+ 
% of CD8+ 
% of CD8+ 
% of CD8+ 
% of CD8+ 
11 
11 
11 
11 
11 
8 (73) 
0 (0) 
1 (9) 
0 (0) 
0 (0) 
3 (27) 
11 (100) 
4 (36) 
10 (91) 
3 (27) 
0 (0) 
0 (0) 
6 (55) 
1 (9) 
8 (73) 
CD19+ B cells cells x109/l 12 5 (42) 7 (58) 0 (0) 
CD27-IgD+IgM+ 
CD21lowCD38low 
CD27+IgD+ 
CD27+IgD- 
CD38++IgM+ 
CD38++IgM- 
Naive 
Activated 
Marginal zone-like 
Switched memory 
Transitional 
Plasmablasts 
% of CD19+ 
% of CD19+ 
% of CD19+ 
% of CD19+ 
% of CD19+ 
% of CD19+ 
11 
11 
11 
11 
11 
10 
6 (55) 
0 (0) 
1 (9) 
1 (9) 
0 (0) 
3 (30) 
3 (27) 
0 (0) 
10 (91) 
7 (64) 
9 (82) 
5 (50) 
2 (18) 
11 (100) 
0 (0) 
3 (27) 
2 (18) 
2 (20) 
DNT double negative T cells, N number patients, TCM central memory T cells, TCR T cell receptor, TEM effector 
memory T cells. 
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Table 8. Antibody responses to 10 serotypes of an unconjugated 23-valent pneumococcal 
polysaccharide vaccine (Pneumovax ®) in eight patients with cartilage-hair hypoplasia. 
Specific antibody deficiency was defined as a fourfold rise in antibody titers and post-
immunization antibody levels ≥ 0.35 µg/ml to less than 70% of serotypes. 
 
Patient Age at 
immunization, years 
Percentage of 
reactive serotypes  
Specific antibody 
deficiency 
1 23 10% Yes 
2 39 60% Yes 
3 40 20% Yes 
4 44 60% Yes 
5 46 50% Yes 
6 58 30% Yes 
7 65 70% No 
8 67 30% Yes 
 
 
We analyzed the laboratory results (as medians) in various age groups (children, young adults 
18-44 years and adults >45 years). Patients aged 45 years or older (n = 18) showed higher 
neutrophil (p = 0.020) and CD4+ (p = 0.025) counts, as well as higher IgA (p = 0.001) and IgG 
(p = 0.048) levels than younger patients. Children demonstrated higher B cell counts (p = 
0.039) and lower concentrations of antibodies to tetanus toxoid (p = 0.043) compared with 
adult patients.  
 
We did not analyze correlations of B and T cell subpopulations with clinical features due to 
the modest number of evaluated individuals. The exceptions included CD4+, CD8+, naive 
thymic T cells and CD19+CD27+ memory B cells that were all tested in the majority of study 
patients. The type of RMRP mutation did not correlate with any clinical or laboratory feature.  
Multiple regression analysis detected the association between warts and higher IgG levels (p 
= 0.020), as well as between otitis media and lower neutrophil counts (p = 0.011). No other 
significant correlations were observed. 
 
 
5.4. Lung imaging (Study III) 
 
HRCT showed a high prevalence of lung abnormalities in 20 out of 34 patients. Bronchiectasis 
was diagnosed by HRCT in 10 patients (29%, 10/34), aged from 29 to 68 years. Bronchiectasis 
was unilateral in two patients and bilateral in eight patients. The most common location of 
bronchiectasis was in the lower lobes and right middle lobe, but bronchiectasis was observed 
also in all other lobes. Additional findings on HRCT were acute inflammatory changes (n = 3), 
fibrosis-like changes (n = 6) and non-specific subpleural nodules of ≤ 0.5 cm in size (n = 8).  
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MRI showed lung abnormalities in 8 out of 16 patients. However, of the five patients with 
bronchiectasis for whom both HRCT and MRI were performed, only three patients had MRI 
score of ≥7 points.  
Nevertheless, there was a significant correlation between HRCT and MRI scores. The overall 
rho was 0.820 (p <0.001) and it ranged from 0.535 to 1.000 for different parameters 
evaluated, with p <0.001 for most of the variables.  
 
5.5. Malignancies (Study IV) 
During the follow-up, 21 out of 80 patients (31%, all adults) developed malignancy, mostly 
skin cancers and lymphomas (Table 9). Importantly, of the 15 patients with non-skin 
malignancies, more than half (8/15, 53%) demonstrated no clinical manifestations of 
immunodeficiency prior to the development of cancer. 
 
Table 9. Malignancies diagnosed in 80 patients with cartilage-hair hypoplasia during the 30-
year follow-up. 
Type of malignancy Number of 
patients 
Outcome at the end of the follow-up 
Lymphoma 9 Four (44%) alive, five (56%) deceased 
Skin cancer 
   Basal cell carcinoma 
   Squamous cell carcinoma 
   Both types 
15 
   11 
   2 
   2 
Thirteen (87%) alive, one deceased 
from other type of malignancy and one 
deceased from causes other than 
cancer 
Lip squamous cell carcinoma 1 Deceased 
Myelodysplasia 1 Deceased from causes other than 
cancer 
Neuroendocrine carcinoma 1 Deceased 
Plasmacytoma 1 Alive 
Thyroid carcinoma 1 Alive 
Vocal cord carcinoma 1 Alive 
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Lymphoma was mostly diagnosed in young adults (median age 32.5 years, range 20.2-45.4 
years) and was fatal in 5/9 (56%) of patients (Table 10). In one of the survivors, the primary 
tumor was diagnosed at an early stage (I) due to a scheduled abdominal ultrasound, and the 
patient remained cancer-free seven years after chemotherapy. Another patient was 
successfully treated despite the advanced stage (IV) at diagnosis, however, the disease 
recurred 15 years later. This recurrence was noticed at the scheduled abdominal ultrasound 
and treated successfully leading to complete resolution. Another survivor had a mucosa-
associated lymphoid tissue lymphoma, which was diagnosed at an early stage (I) by 
gastroscopy performed for abdominal pain and was treated successfully by surgical resection 
only, with no recurrence during 14 years. 
 
Table 10. Description of lymphoma cases in the cohort of 80 patients with cartilage-hair 
hypoplasia. Age group (in years) describes age at the diagnosis of lymphoma. 
Case Age 
group 
Type of lymphoma Location of the 
primary tumor 
Stage at 
diagnosis 
Outcome at the latest follow-up 
1 20-30 Diffuse large B cell Spleen I Alive and cancer-free 
2 20-30 Nodular sclerosing 
Hodgkin 
Chest III B Accidental death 
3 20-30 Unspecified Mediastinum IV Death from cancer 
4 20-30 MALT Stomach I Alive and cancer-free 
5* 30-40 Large cell anaplastic Lymph node I A Two relapses, death from cancer 
6 30-40 Diffuse large B cell Disseminated IV Relapse, alive, complete resolution  
7 30-40 Small lymphocytic Lymph nodes NA Death from cancer  
8 40-50 Burkitt-like Intra-abdominal 
adipose tissue 
IV Death from cancer  
9 40-50 Diffuse large B cell Mediastinum IV Death from cancer  
MALT mucosa-associated lymphoid tissue; NA not available 
* This case has been described previously (Taskinen, et al. 2013) 
 
 
Fifteen patients were diagnosed with skin cancer, mostly basal cell carcinomas. The median 
age at diagnosis of the first skin cancer was 45.9 years (range 24.5-67.4 years). The median 
number of skin cancer episodes per patient was two (range 1-9). Altogether, nine patients 
required therapy for actinic keratosis, and five of them were later diagnosed with skin cancer. 
All skin malignancies were restricted to the face, head and upper limbs. 
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SIR for all malignancies in patients with CHH was 9.4 (95% CI 6.4-13) and lymphoid and 
hematopoietic tissue malignancies (SIR 34, 95% CI 17-60), as well as malignancies of the skin 
(SIR 20, 95% CI 11-32) were the major contributors to this increased incidence (Table 11). 
 
Table 11. The incidence of malignancies in a cohort of 80 patients with cartilage-hair 
hypoplasia during 1987-2016. 
Malignancy Obs Exp SIR 95% CI 
All malignancies 
   Mouth, pharynx 
   Respiratory and intrathoracic organs 
   Skin 
   Endocrine glands 
   Ill-defined or unknown 
   Lymphoid and hematopoietic tissue 
31 
3 
2 
14 
1 
1 
10 
3.31 
0.06 
0.12 
0.71 
0.13 
0.03 
0.29 
9.4 
54 
15 
20 
7.8 
35 
34 
6.4-13*** 
13-140*** 
2.6-48** 
11-32*** 
0.4-34 
2.0-160** 
17-60*** 
CI confidence interval, Exp expected number of malignancies, Obs observed number of malignancies, SIR 
standardized incidence ratio 
* p < 0.05, ** p<0.01, *** p <0.001 
 
 
5.6. Mortality (Study IV) 
 
Altogether, 20 out of 80 patients died during follow-up. Causes of death derived from patient 
records were classified as immunodeficiency-related (n = 15) and -unrelated (n = 5). The 
former included deaths from infections (n = 4, all from pneumonia), underlying respiratory 
diseases (n = 4, all patients had bronchiectasis and two also emphysema) and malignancies (n 
= 7). Deaths from cancer included cases of lymphoma (n = 5), lip squamous cell carcinoma (n 
= 1) and neuroendocrine carcinoma (n = 1). The median age at death was 40.9 years (24.4 
years for death from infections, 40.9 years for death from malignancies and 52.8 years for 
death from respiratory diseases). 
 
Table 12 describes SMRs for 80 patients with CHH for the period from 1987 to 2016, showing 
the significantly higher mortality rates (SMR 7.0, 95% CI 4.3-11), mostly due to lymphoma 
(SMR 60, 95% CI 16-150) and lung disease (SMR 46, 95% CI 9.5-130).  
 
The registered cause of death was “congenital malformations” in four subjects, which referred 
to CHH itself. However, according to the hospital records, the accurate causes of death in 
these patients were pneumonia in three and respiratory failure in one. Another patient had 
“disease of circulatory system” as a registered cause of death, but this subject’s records 
described death from pneumonia. Therefore, the SMR for infections could not be correctly 
calculated and the evaluation of SMR for respiratory diseases was also subject to bias. 
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Table 12. Mortality data in 80 patients with cartilage-hair hypoplasia during 1987-2016. 
Age, years N Disease mortality Obs Exp SMR 95% CI 
0-14 39 All causes 2 0.09 21 2.6-77** 
15-29 27 All causes 4 0.48 8.3 2.3-21** 
30-44 12 All causes 6 0.79 7.6 2.8-17*** 
45-59 2 All causes 7 1.03 6.8 2.7-14*** 
60-74 - All causes 1 0.45 2.2 0.1-13 
Total 80 All causes 
   All diseases 
      Neoplasms 
         Malignant neoplasms 
            Lymphoid/hematopoietic neoplasms 
            Malignant neoplasms of lip 
            Other malignant neoplasms 
         Other neoplasms 
      Circulatory system diseases 
      Respiratory system diseases 
      Congenital malformations 
      Alcohol-related diseases 
   Accidents and violence 
20 
17 
7 
6 
4 
1 
1 
1 
2 
3 
4 
1 
3 
2.85 
1.93 
0.69 
0.68 
0.07 
0.01 
0.13 
0.01 
0.47 
0.07 
0.05 
0.33 
0.90 
7.0 
8.8 
10 
8.8 
60 
75 
7.7 
98 
4.3 
46 
76 
3.0 
3.3 
4.3-11*** 
5.1-14*** 
4.1-21*** 
3.2-19*** 
16-150*** 
1.9-420* 
0.2-43 
2.5-540* 
0.5-16 
9.5-130*** 
21-190*** 
0.1-17 
0.7-9.8 
CI confidence interval, Exp expected and Obs observed number of deaths, N number of patients, SMR 
standardized mortality ratio 
* p <0.05, ** p <0.01, *** p <0.001 
 
 
5.7. Factors associated with adverse outcome 
 
5.7.1. Factors associated with the development of bronchiectasis (Study III) 
 
Patients with bronchiectasis were significantly older (median age 59.5 years) than patients 
without bronchiectasis (median age 36.5 years, p 0.023). However, bronchiectasis was 
diagnosed also in a 29-year-old patient. Patients with bronchiectasis tended to report more 
chronic cough, sinus infections and pneumonia than patients without bronchiectasis, but the 
differences were not statistically significant. Six of the study patients reported smoking, four 
of them had bronchiectasis. However, when controlled for age, the association of smoking 
with bronchiectasis became insignificant.  
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Patients with bronchiectasis had higher serum levels of IgG (p = 0.013), as well as higher 
leukocytes (p = 0.034), lymphocytes (p = 0.008), and NK cells (p = 0.008) compared with 
patients without bronchiectasis. We also reported a trend for higher counts of T cells, 
including both CD4+ and CD8+ cells, in patients with bronchiectasis. However, leukocyte, 
lymphocyte, CD3+, CD4+ and CD8+ T cells, and NK cell counts correlated significantly with age 
(rho 0.417 (p = 0.014), 0.588 (p = 0.000), 0.484 (p = 0.004), 0.554 (p = 0.001), 0.403 (p = 0.020) 
and 0.415 (p = 0.016) respectively), while IgG levels correlated with lymphocyte counts (rho 
0.439, p = 0.013).  
Insufficient levels of serum antibodies to tetanus toxoid were detected in two out of 27 
patients, both aged 68 years, and one of them was diagnosed with bronchiectasis. Responses 
to polysaccharide pneumococcal vaccine were abnormal in those with and without 
bronchiectasis. Retrospective data on lymphocyte proliferative responses were available for 
eight patients. Six of them (all without bronchiectasis) demonstrated decreased responses. 
Noteworthily, two patients with bronchiectasis had normal results of all the evaluated 
laboratory parameters, with the exception of low counts of CD27+IgD+ memory B cells. 
When we applied multiple logistic regression analysis, of all variables, only higher NK cell 
counts remained significantly associated with the presence of bronchiectasis (p = 0.026, B 
coefficient 8.8).  
 
5.7.2. Factors associated with the development of malignancy (Study IV) 
 
Different factors related to the development of certain malignancies. Childhood 
manifestations associated with lymphoma, while features present in adulthood correlated 
with skin cancer (Table 13). Only recurrent pneumonia in childhood associated significantly 
with lymphoma (odds ratio 14, 95% CI 1.4-150, p <0.05). 
Skin cancer was significantly associated with actinic keratosis and with warts in adulthood, 
but not in childhood (Table 13). All patients with skin malignancies manifested either actinic 
keratosis (n = 5), warts in adulthood (n = 6) or both (n = 4) prior to the development of skin 
cancer.  
When linear regression analysis was applied, birth length SD score correlated significantly 
with the age at diagnosis of the first malignancy (p = 0.0029), lymphoma (p = 0.011) and the 
first skin cancer (p = 0.014), demonstrating that patients with shorter length at birth 
developed malignancies at an earlier age (Figure 7). 
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Table 13. Risk factors for the development of lymphoma or skin cancer in a cohort of 80 
patients with CHH in the multivariate regression analysis adjusted for age and gender. 
 Prevalence in patients 
with outcome, N (%) 
Prevalence in patients 
without outcome, N (%) 
OR 95% CI 
Development of lymphoma 
Recurrent pneumonia in childhood 3/9 (33) 2/70 (3) 14 1.4-150* 
Development of skin cancer 
Actinic keratosis 
Warts in adulthood 
9/15 (60) 
10/15 (67) 
4/65 (6) 
12/63 (19) 
20 
7.6 
4.5-88*** 
2.1-27** 
CI confidence interval, N number, OR odds ratio 
* p <0.05, ** p <0.01, *** p <0.001 
 
5.7.3. Factors associated with mortality (Study IV) 
 
Due to the small number of infection- and lung disease-related deaths, and the distribution 
of events in the subgroups of patients, the multivariate analysis could not be performed 
separately for specific causes of death. 
 
In the analysis of the factors associated with immunodeficiency-related death (due to 
infections, respiratory disease and malignancies, all combined), Hirschsprung disease, 
pneumonia in the first year of life, and autoimmune diseases and recurrent pneumonia in 
adulthood appeared significant in the multivariate regression analysis (Table 14). 
In addition, severe short stature at birth and symptoms of CID were associated with higher 
mortality (Table 15). Patients with severe short stature at birth (< -4.0 SD) had higher SMR for 
all causes of deaths than those with normal birth length (> -2.0 SD), (SMR/SMR ratio 5.4, 95% 
CI 1.5-20) (Table 15). Subjects with symptoms of CID had higher all-cause mortality compared 
with patients with asymptomatic immunodeficiency (SMR/SMR ratio 3.9, 95% CI 1.3-11) 
(Table 15).
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Figure 7. The association of the shorter birth length with the earlier age at development of 
the first malignancy (A), lymphoma (B) and the first skin cancer (C) in 80 patients with CHH. 
A  
B  C  
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Table 14. Risk factors for immunodeficiency-related death in a cohort of 80 patients with cartilage-hair hypoplasia. All study 
variables were first analyzed by univariate analysis adjusted for age and gender (Model 1). Variables proven significant were then 
grouped by the time of presentation. Significantly (correlation coefficient >0.6) correlating variables were excluded and the 
remaining variables were combined for the multivariate analysis, where clinical factors were analyzed separately in childhood and 
adulthood (Model 2). 
Risk factors for immunodeficiency-
related death 
Prevalence in 
patients with 
outcome, N (%) 
Prevalence in 
patients without 
outcome, N (%) 
Model 1 Spearman’s 
correlation 
coefficient 
Included in 
multivariate 
analysis 
Model 2 
OR 95% CI OR 95% CI 
Clinical features in the first year of life 
   A. Hirschsprung disease 
   B. Pneumonia 
 
4/15 (27) 
5/14 (36) 
 
2/65 (3) 
4/63 (6 
 
15 
7.8 
 
1.8-130* 
1.7-36** 
0.4: A/B 0.6: B/C 
0.4: B/D, 
B/F, D/K 
0.3: A/F, 
D/J 
0.2: A/D, 
B/I, B/J 
0.1: A/I, 
A/J, B/K, 
D/F, D/I  
0.0: A/K 
 
 
+ 
+ 
 
7.2 
7.6 
 
1.04-55* 
1.3-43* 
Clinical features in childhood 
   C. Pneumonia   
   D. Recurrent rhinosinusitis 
   E. CID 
 
10/15 (67) 
4/14 (29) 
4/15 (27) 
 
13/64 (20) 
3/61 (5) 
3/65 (5) 
 
8.2 
6.8 
6.7 
 
2.3-29** 
1.1-43* 
1.2-38* 
0.7: C/E 
0.3: C/D   
 
- 
+ 
- 
 
 
1.6 
 
 
0.1-21 
 
Clinical features in adulthood 
   F. Autoimmune disease 
   G. CID 
   H. Pneumonia 
   I. Recurrent pneumonia  
   J. Recurrent otitis media 
   K. Recurrent rhinosinusitis 
   L. Low serum levels of IgG in adulthood 
 
5/13 (39) 
7/13 (54) 
7/13 (54) 
5/13 (39) 
4/13 (31) 
6/13 (46) 
4/10 (40) 
 
1/65 (2) 
10/65 (15) 
11/65 (17) 
2/65 (3) 
3/65 (5) 
9/64 (14) 
2/38 (5) 
 
42 
6.8 
5.9 
22 
11 
5.5 
23 
 
4.2-410** 
1.8-26** 
1.6-22** 
3.3-140** 
1.8-63* 
1.4-22* 
2.3-230** 
0.6: F/G, 
F/L, H/I 
0.4: J/K, 
I/J, I/K 
0.3: F/I 
0.1: F/J, 
F/K 
 
 
+ 
- 
- 
+ 
+ 
+ 
- 
 
39 
 
 
19 
4.2 
2.4 
 
3.5-430** 
 
 
2.6-140** 
0.4-43 
0.3-18 
CI confidence interval, CID combined immunodeficiency, Ig immunoglobulin, OR odds ratio 
* p <0.05, ** p <0.01 
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Table 15. Mortality from selected causes in 80 patients with cartilage-hair hypoplasia grouped by birth length SD score and by the 
category of immunodeficiency (ID). 
 Obs Exp SMR 95% CI Obs Exp SMR 95% CI 
Causes of death  By birth length categories# By categories of ID at recruitment 
 
All deaths 
    Neoplasms 
       Lymphoid/hematopoietic neoplasms 
    Respiratory diseases 
Normal birth length (SD > -2.0, n = 28) Asymptomatic ID (n = 52) 
6 
3 
2 
1 
1.47 
0.44 
0.04 
0.04 
4.1 
6.7 
53 
24 
1.5-8.9** 
1.4-20* 
6.4-190** 
0.6-130 
10 
3 
2 
2 
2.07 
0.49 
0.05 
0.05 
4.8 
6.2 
43 
44 
2.3-8.9*** 
1.3-18* 
5.2-150** 
5.3-160** 
 
All deaths 
    Neoplasms 
       Lymphoid/hematopoietic neoplasms 
    Respiratory diseases 
Moderately short birth length (SD -2.0 - -4.0, n = 39) Symptoms of humoral ID (n = 18) 
8 
3 
2 
0 
1.11 
0.20 
0.02 
0.02 
7.2 
15 
87 
0.0 
3.1-14*** 
3.1-44** 
11-320*** 
0.0-190 
2 
0 
0 
0 
0.34 
0.09 
0.01 
0.01 
5.9 
0.0 
0.0 
0.0 
0.7-21 
0.0-41 
0.0-400 
0.0-540 
    
All deaths 
    Neoplasms 
       Lymphoid/hematopoietic neoplasms 
    Respiratory diseases 
Severely short birth length (SD < -4.0, n = 13) Symptoms of combined ID (n = 10) 
6 
1 
0 
2 
0.27 
0.05 
0.01 
0.00 
22 
20 
0.0 
430 
8.1-48*** 
0.5-110 
0.0-600 
52-1600*** 
8 
4 
2 
1 
0.43 
0.12 
0.01 
0.01 
19 
34 
180 
79 
8.0-36*** 
9.3-87*** 
22-650*** 
2.0-440* 
CI confidence interval, Exp expected number of deaths, n number of patients, Obs observed number of deaths, SD standard deviation, SMR standardized 
mortality ratios 
* p <0.05, ** p <0.01, *** p <0.001 
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5.8. Telomere length (Study I) 
 
RTL was measured from 228 samples, including patients (n = 48), first-degree relatives (n = 
86) and healthy unrelated controls (n = 94). RTL was not influenced by sex, but we 
demonstrated a significant negative correlation between RTL and age in mutation carriers (rho 
-0.482, p < 0.001) and non-carriers (rho -0.498, p < 0.001). Remarkably, the correlation of RTL 
with age could not be demonstrated in patients with CHH (rho -0.236, p = 0.107).  
In the age-group analysis, the vast majority of children with CHH had short telomeres for age 
(89%, 8/9). Short telomeres were detected in two thirds of patients aged 18.1-40.0 years 
(11/17, 65%), but in only 27% (6/22) of those aged over 40.1 years (Table 16). 
 
 
Table 16. Relative telomere length in patients with cartilage-hair hypoplasia. 
 
Age group, years N RTL, median (range) Short RTL, N (%) Average RTL, N (%) Long RTL, N (%) 
6.0-18.0 9 1.12 (0.88-1.31) 8 (89) 1 (11) 0 (0) 
18.1-40.0 17 1.08 (0.91-1.72) 11 (65) 2 (12) 4 (23) 
40.1-70.8 22 1.06 (0.70-1.81) 6 (27) 8 (36) 8 (37) 
All ages 48 1.07 (0.70-1.81) 25 (52) 11 (23) 12 (25) 
N number of patients, RTL relative telomere length 
 
 
 
5.8.1. RTL in patients, RMRP mutation carriers and mutation-negative individuals 
 
Significantly more patients with CHH had short RTL (52%, 25/48) compared with mutation 
carriers (20%, 15/74, p <0.001) or healthy non-carriers (29%, 31/106, p = 0.011) (Table 17). In 
the comparison of patients with CHH with RMRP mutation-negative individuals, significantly 
more children and young adults with CHH demonstrated short telomeres (p = 0.016 and p = 
0.047 respectively), but not older individuals (p = 0.769) (Table 17). When RTL itself was 
compared between patients with CHH and healthy controls, RTL was significantly shorter in 
children (p = 0.008), but not in adults with CHH (Figure 8). 
In the control group, we detected age- and sex-matched RMRP mutation-negative controls for 
40 patients with CHH. In this case-control analysis patients demonstrated significantly shorter 
RTL (p = 0.017) (Figure 9). This difference was explained by shorter RTL in children (p = 0.015, 
n = 8 pairs), whereas young adults showed only a trend for shorter RTL (p = 0.069, n = 14 pairs) 
and no difference was seen in older individuals (p = 0.443, n = 18 pairs). 
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Table 17. Comparison of relative telomere length categories between patients with cartilage-
hair hypoplasia, RMRP mutation carriers and non-carriers. 
 
Age group, years N Short RTL, N (%) Average RTL, N (%) Long RTL, N (%) 
Patiens 
6.0-18.0 
18.1-40.0 
40.1-70.8 
All ages 
9 
17 
22 
48 
8 (89%) 
11 (65%) 
6 (27%) 
25 (52%) 
1 (11%) 
2 (11.5%) 
8 (36.5%) 
11 (23%) 
0 (0%) 
4 (23.5%) 
8 (36.5%) 
12 (25%) 
RMRP mutation carriers 
5.0-18.0 
18.1-40.0 
40.1-70.8 
All ages 
17 
12 
45 
74 
7 (41%) 
3 (25%) 
5 (11%) 
15 (20%) 
6 (35%) 
5 (42%) 
21 (47%) 
32 (43%) 
4 (24%) 
4 (33%) 
19 (42%) 
27 (37%) 
Non-carriers 
6.0-18.0 
18.1-40.0 
40.1-70.8 
All ages 
19 
40 
47 
106 
7 (37%) 
14 (35%) 
11 (23%) 
31 (29%) 
5 (26%) 
17 (43%) 
22 (47%) 
45 (43%) 
7 (37%) 
9 (22%) 
14 (30%) 
30 (28%) 
N number of patients, RTL relative telomere length 
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Figure 8. Relative telomere length in patients with cartilage-hair hypoplasia, RMRP mutation 
carriers and non-carriers, grouped by age categories. Children with cartilage-hair hypoplasia 
demonstrated significantly shorter telomeres (p = 0.008), but not young adults nor adults. o 
outlier, * extreme outlier. 
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Figure 9. Relative telomere length in 40 patients with cartilage-hair hypoplasia compared with 
40 age- and gender-matched healthy RMRP mutation non-carriers. Telomere length was 
significantly shorter in children with CHH (p = 0.015, n = 8 pairs), but not young adults (p = 
0.069, n = 14 pairs) nor adults (p = 0.443, n = 18 pairs). o outlier, * extreme outlier. 
 
 
 
 
 
 
5.8.2. Correlation of RTL with CHH-related features 
 
We examined all available clinical and laboratory data to find correlations with RTL itself or 
RTL categories. Variables included sex, the type of RMRP mutation, the degree of growth 
failure, the history of obesity, smoking, blood transfusions, immunoglobulin substitution, 
hormone or immunosuppressive therapy, various infectious manifestations separately or in 
combinations, fibrosis-like lung changes, malignancies, and analyzed laboratory parameters. 
No significant correlations were detected. 
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6. DISCUSSION 
 
This study explored clinical and pathogenetic features and the associated outcomes in a large 
cohort of Finnish patients with CHH. Previous research has benefited from an exceptionally 
large number of patients with CHH living in Finland. These landmark studies substantially 
expanded our knowledge of CHH and led to the discovery of the genetic defect underlying 
this disease. Our study described numerous novel findings adding to our understanding of 
the pathogenesis, immune phenotype, disease course and prognosis in CHH. 
 
6.1. Clinical and immunologic phenotype 
 
We analyzed clinical and immunologic data in the unique sample of 56 pediatric and adult 
subjects with CHH (Study II). We could not demonstrate any significant correlations between 
clinical features and laboratory parameters, and few patients reported serious complications 
despite abnormal laboratory values. Consistently, in Study IV we showed that clinical 
symptoms were more valuable as prognostic factors than laboratory parameters. 
Our long-term follow-up Study IV allowed for determination of clinical patterns of 
immunodeficiency in CHH. Half of the patients in our cohort remained clinically asymptomatic 
for decades. Some RMRP gene mutations induce a more severe immunodeficiency (Thiel and 
Rauch 2011), and the predominance of n.71A>G mutation in Finnish patients can result in 
milder phenotypes. However, many of the asymptomatic subjects either progressed to the 
late-onset immunodeficiency in adulthood, or developed malignancy, often fatal. Therefore, 
all patients with CHH, even completely asymptomatic, should be carefully followed. 
All of our patients in Study IV who had symptomatic immunodeficiency presented with 
infections typical for defects in humoral immunity, including recurrent RTI, bacterial skin 
infections and/or sepsis. The spectrum of pathogens causing these infections was also 
consistent with humoral immunodeficiency. This clinical presentation is in contrast with low 
rates of hypogammaglobulinemia in our cohort. However, many patients had low counts of 
B cells. Altogether, these findings suggest that despite having normal or even high levels of 
IgG, subjects with CHH behave like antibody-deficient patients and are unable to combat 
common bacterial pathogens. This pattern should be recognized, and patients suffering from 
recurrent infections should be considered for prophylactic antibiotics and/or a trial of IGRT 
irrespective of serum IgG levels. 
Despite low counts of B cells in many subjects, IgG levels were normal in all but one patient 
in Study II, including measurements available prior to the commencement of IGRT in two 
subjects. Paradoxically, high IgG levels were the most common immunoglobulin abnormality 
in patients from Study IV. Serum immunoglobulin levels are maintained by long-lived plasma 
cells, and thus do not reflect the ongoing effective immunoglobulin production (Blanco, et al. 
2018). In patients with classical clinical signs of humoral immunodeficiency, including some 
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patients with CHH, IGRT should be trialed irrespectively of IgG levels. This approach has shown 
efficacy in preventing infections in patients with hyper-IgE syndrome induced by STAT3 
mutations, who benefit significantly from IGRT despite having normal levels of IgG 
(Chandesris, et al. 2012). The potential efficacy of IGRT is supported by the finding of a large 
proportion of patients with CHH presenting with low memory B cell counts. The observed 
pattern of abnormalities in B cell subpopulations is consistent with impaired B cell production 
and germinal center defect, while decreased counts of CD27+ B cells suggest maturation or 
survival defect (Driessen, et al. 2011), supporting the consideration of IGRT in CHH. 
The inclusion of children and elderly subjects into the study allowed us to record and analyze 
aged-related trends in immunological parameters. In general population, serum 
immunoglobulin levels increase with age, whereas total lymphocyte and B cell counts reach 
the nadir at around six months of life and slowly decline thereafter (Blanco, et al. 2018). We 
observed the same changes in the laboratory parameters in our Study II cohort. However, 
higher numbers of CD4+ cells in adults with CHH and the increased CD8+ and CD16/56+ cell 
counts in children with CHH remain to be explained in future studies. 
Protective levels of anti-tetanus toxoid antibodies were present in most of the subjects in 
Study II. By contrast, we reported for the first time a high prevalence of specific antibody 
deficiency in patients with CHH (88%). Of CHH individuals with specific antibody deficiency, 
57% had clinical features suggesting CID. However, in Study IV, in which we identified 12 more 
patients who had been tested for the pneumococcal polysaccharide vaccine responses 
(abnormal in seven), specific antibody deficiency showed no correlation with clinical 
symptoms or outcomes. 
In contract to the previous studies in Finnish patients with CHH, we demonstrated high rates 
(20%) of opportunistic infections (Study IV). These were, however, mostly confined to 
mucocutaneous viral and fungal infections. The prevalence of cutaneous warts in patients 
with CHH was higher than in healthy population (33-34% vs 5%) (Leiding and Holland 2012). 
At the time of the follow-up visit, six children and eight adults presented with warts. 
Interestingly, as many as 50% of the subjects with specific antibody deficiency reported a 
history of warts in Study II, suggesting more clinically evident CID.  
Basal cell carcinoma was the most common malignancy in our patients, however, it is rarely 
described in individuals with other PID. Single cases have been reported in patients with 
common variable immunodeficiency (Todorovic, et al. 2014) and WHIM syndrome (Beaussant 
Cohen, et al. 2012). The latter study highlights the role of human papilloma virus in the 
development of skin cancer, which is also demonstrated by the increased risk of cutaneous 
malignancy in epidermodysplasia verruciformis (Accardi and Gheit 2014). We showed that 
warts in adulthood, but not in childhood, were associated with the development of skin 
cancer in CHH. This suggests the benign nature of warts in children, but in adulthood warts 
can indicate impaired skin immunity and can result in malignant transformation. 
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Consistent with previous studies, we reported a high incidence of malignancy in CHH, mostly 
due to lymphomas and skin cancers (Study IV). Compared with earlier reports (Taskinen, et 
al. 2008), we described improved survival after the diagnosis of lymphoma (4/9 patients alive, 
44%), mostly due to early detection of tumors. Our data underscores the importance of 
regular cancer screening and thorough diagnostic work-up of symptomatic patients.  
 
6.2. The role of telomere machinery in CHH 
 
We expanded the knowledge of CHH pathogenesis by demonstrating shorter telomeres in 
children with CHH (Study I). Our results have been later confirmed by Aubert et al (Aubert, et 
al. 2017). They measured telomere length and telomerase activity in lymphocytes from 15 
patients with CHH (including two adults) and eight RMRP mutation carriers. They used a 
different method of telomere measuring (flow-fluorescent in situ hybridization) and 
compared their results with a much larger cohort of healthy individuals (n = 835). Consistent 
with our findings, telomeres were significantly shorter in subjects with CHH, and impaired 
telomerase activity was also described. Our discovery of shorter telomeres in children, but 
not adults with CHH, was later supported by the demonstration of the same trend in patients 
with pathogenic variants in telomere machinery genes (Alder, et al. 2018).  
Disorder of telomere maintenance add to the impaired cell biology and together can explain 
the majority of CHH features, including short stature, immunodeficiency, increased risk of 
malignancy, hypoplastic anemia, lung disease, enteropathy and impaired spermatogenesis 
(Alder, et al. 2018, Wagner, et al. 2018). T cells in CHH demonstrate increased apoptosis (de 
la Fuente, et al. 2011), and the underlying mechanism for this can involve the activation of 
DNA damage response triggered by critical shortening of telomeres (Alder, et al. 2018). Very 
recently, T cell immunodeficiency has been demonstrated in a cohort of patients with 
telomeropathies in the absence of bone marrow failure (Wagner, et al. 2018). Interestingly, 
the most common infections in this cohort were caused by herpes viruses, echoing the 
predisposition to severe varicella in CHH. Moreover, abnormalities in T cell populations in 
subjects with short telomere syndromes included depletion of naive T cells and accumulation 
of effector memory CD8+ cells, similar to our findings in patients with CHH in Study II. 
The pathogenesis of malignancies in CHH is probably multifactorial and includes the defects 
in cell proliferation and apoptosis. Disorders of telomere maintenance, such as dyskeratosis 
congenita, are characterized by increased susceptibility to malignancies, mostly head and 
neck squamous cell carcinomas and skin cancers (Alter, et al. 2009). Our findings of impaired 
telomere biology offer an additional risk factor for the increased cancer rates in patients with 
CHH. In Study IV, we demonstrated that actinic keratosis was the most significant risk factor 
for skin cancer, which developed on sun-exposed skin areas in patients with CHH. Ultraviolet 
exposure can exhibit detrimental effect on cells with impaired telomere and DNA repair 
machinery, explaining the high susceptibility to skin malignancies in CHH (Anic, et al. 2013). 
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Lung fibrosis is an established manifestation of dyskeratosis congenita, and short telomeres 
have been demonstrated also in cases of idiopathic pulmonary fibrosis and early-onset 
emphysema (Alder, et al. 2018, Armanios, et al. 2007). Apart from bronchiectasis, we 
reported high rates (18%) of fibrosis-like changes in subjects with CHH in Study III and we also 
described two patients with fatal emphysema in Study IV. Lung disease in patients with 
telomeropathies manifests in adulthood (Alder, et al. 2018), and in Study IV we demonstrated 
that, compared with deaths due to infections and malignancies, mortality attributed to 
respiratory disease in patients with CHH was highest in the older age group. Therefore, some 
cases of lung disease in CHH can be linked to telomere abnormalities and this hypothesis 
requires further studies. 
We acknowledge that, although telomere length differed significantly in patients with CHH 
and healthy controls, the actual numbers behind these differences were rather small, and 
additional research is necessary to confirm these findings and investigate whether short 
telomeres underlie clinical features of CHH. 
 
6.3. Lung disease in CHH 
 
We reported a high prevalence (29%) of bronchiectasis in a random cohort of 34 Finnish 
patients with CHH (Study III). This result corroborates previous studies of moderately or 
severely affected CHH cohorts, where the prevalence ranged from 43 to 52% (Bordon, et al. 
2010, Toiviainen-Salo, et al. 2008). We showed that bronchiectasis can develop in patients 
with CHH even in the absence of apparent immunodeficiency. Most of the patients in Study 
III had no or minor respiratory symptoms and had never underwent lung HRCT previously, in 
line with the lack of clinical indication for detailed lung imaging. However, half of the subjects 
with bronchiectasis reported daily cough ongoing for at least one year. This calls for regular 
lung imaging even in mildly symptomatic patients.  
Clinical significance of asymptomatic bronchiectasis in healthy persons is an area of debate. 
However, in patients with immunodeficiency, pulmonary diseases contribute to poor 
prognosis (Sullivan KE 2014). In patients with CHH, lung changes should thus be actively 
searched for and treated if present. In Study III, we diagnosed bronchiectasis in a patient as 
young as 29 years and, in Study IV, we described additional cases of bronchiectasis in 10-, 14- 
and 16-year-old children. This emphasizes the necessity of early screening, in order to 
commence proper investigations and treatment in a timely manner. 
The high prevalence of bronchiectasis in our cohort could be partially explained by female 
gender predominance, as bronchiectasis occur more commonly in women than men (Kwak, 
et al. 2010). However, of the 10 patients with bronchiectasis in Study III, three were men, and 
the proportion of women was actually higher in the group of patients without bronchiectasis. 
We identified additional 11 patients diagnosed with bronchiectasis in Study IV, all females. 
However, when all 37 cases of bronchiectasis from Study IV were analyzed, the proportion of 
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females in patients with and without bronchiectasis did not differ significantly (16/21 and 
13/26 respectively, p = 1.000). 
The prevalence of bronchiectasis in the general population increases with age (Kwak, et al. 
2010), and in our sample, six out of 10 patients with bronchiectasis were aged over 58 years. 
The prevalence of bronchiectasis in this age group in general population is as high as 15% 
(Kwak, et al. 2010), but it was significantly higher (55%) in our patients. Furthermore, the 
majority (9/11) of the additional cases of bronchiectasis from Study IV were diagnosed in 
subjects younger than 58 years. 
The history of sinus infections correlates positively with the presence of bronchiectasis in the 
general population (Guilemany, et al. 2009). However, we could not confirm this correlation 
in Study III. Still, there was a trend for more sinus and middle ear infections, as well as 
pneumonia in CHH patients with bronchiectasis. Our results could be affected by the 
retrospective nature of clinical data and by the small number of patients included in the study.  
 
We previously reported higher numbers of T cells and higher IgG levels in CHH patients with 
increased susceptibility to infections (Makitie, et al. 1998, Makitie, et al. 2000). In Study III, 
we showed the same trend in CHH patients with bronchiectasis. The possible explanations 
include smoking, chronic infections or inflammation in the respiratory tract and 
bronchiectasis-induced systemic immune response (Daheshia, et al. 2012). We recognize the 
possibility of bias arising from exclusion of three subjects receiving IGRT from the analysis of 
IgG levels. However, when we included pre-IGRT IgG levels available for two patients into the 
analysis, the results were equal and became even more significant. Whatever the underlying 
mechanisms are, clinically those with higher, rather than lower, cell counts and IgG 
concentrations surprisingly appeared to be at risk of having bronchiectasis. However, these 
laboratory parameters correlated with age and may just represent cumulation of 
bronchiectasis in the older age group in Study III. 
 
Almost one third of patients had previously been diagnosed with asthma by a physician, but, 
unfortunately, we were not able to assess the individual diagnostic criteria for asthma. Given 
that the prevalence of asthma in the general population of Finnish adults is around 6% 
(Kotaniemi, et al. 2002), this diagnosis was significantly more common in patients with CHH 
(21-24%). Asthma may have been misdiagnosed as the cause of respiratory symptoms in 
some of the patients. We have later demonstrated the high incidence of autoimmunity in 
patients with CHH, and asthma diagnosis may thus reflect immune dysregulation 
(Vakkilainen, et al. 2018). The latter can also explain the higher prevalence of anamnestic 
allergic rhinitis in our cohort (41-44%) when compared with the general Finnish population 
(15-25%) (Remes, et al. 1998). On the other hand, chronic upper respiratory symptoms 
triggered by infections can be misinterpreted by patients or misdiagnosed by physicians as 
allergy. Asthma evaluation by spirometry in CHH is complicated due to short-stature since the 
height-related values may be normal even when pulmonary function is diminished, whereas 
age-related values may be falsely low. Incorporating sitting height measurement into 
spirometry assessment of patients with CHH may be beneficial. We did not assess lung 
diffusion capacity and it should be evaluated in future studies. 
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Chronic respiratory symptoms in patients with CHH should not be attributed to asthma until 
lung imaging is performed. Correct diagnosis is crucial for management, for instance, inhaled 
corticosteroids in adults with bronchiectasis increase the risk of lung infections, and thus 
should be used only after obtaining objective evidence of their benefit (Chang, et al. 2018). 
The comparison of HRCT and MRI scores in our study patients confirmed that HRCT detects 
minor pathological changes in small airways better than MRI. Lung HRCT remains the gold 
standard for diagnosing bronchiectasis, but we demonstrated a good performance of lung 
MRI in evaluation of bronchiectasis in patients with CHH. Lung MRI may have a role in the 
follow-up of lung status, reducing repeated radiation exposure. 
 
 
6.4. Factors associated with adverse outcomes 
 
There are several obstacles in investigating prognostic correlations in CHH cohorts. First, the 
definition of increased susceptibility to infections is not universal and varies among studies 
(Table 2). Second, children with CHH may be mildly symptomatic and develop clinical signs of 
immunodeficiency only in adulthood (Horn, et al. 2010), and, therefore, studies performed in 
pediatric population can be biased. In addition, laboratory immunologic parameters can 
fluctuate with time, challenging the correlation of phenotype with a single laboratory 
measurement. In addition, only prospective studies with prolonged follow-up can shed light 
on the prognostic factors present in childhood for mortality or the development of 
malignancies in adulthood. Finally, the rarity of the disease results in small number of patients 
recruited to the studies, complicating the statistical analysis. 
We therefore, conducted a prospective long-term follow-up study in a large cohort of 80 
patients with CHH. This landmark study (IV) provided multiple risk factors for 
immunodeficiency-related mortality and for the development of malignancies. 
Hirschsprung disease is a well-recognized co-morbidity in patients with CHH. It demonstrates 
a more severe clinical course and poor prognosis in CHH (Makitie, et al. 2002, Makitie, et al. 
2001). Our data confirmed this association and linked Hirschsprung disease with mortality in 
subjects with CHH. Two mechanisms can explain these findings. First, the high prevalence of 
Hirschsprung disease in individuals with CHH suggests that RMRP contributes to the 
pathogenesis of Hirschsprung disease, probably via impaired gene regulation. Cases of CHH 
with Hirschsprung disease may thus represent severely abnormal RMRP function resulting in 
a more profound immunodeficiency. Second, enterocolitis associated with Hirschsprung 
disease predisposes patients to infections with gut microorganisms and interferes with 
gastrointestinal mucosal immunity (Gosain and Brinkman 2015, Zhao, et al. 2010). 
In addition, shorter birth length correlates with increased risk of infections in CHH (Makitie 
and Kaitila 1993, Rider, et al. 2009), and we demonstrated that birth length Z score < -4.0 
associated with mortality. Patients with CHH and less severe skeletal manifestations can also 
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develop serious lung damage or fatal malignancies (Klemetti, et al. 2017), however, extreme 
short stature probably reflects the higher degree of the disruption of RMRP function and can 
thus associate with more profound immunodeficiency.  
Recently, the development of autoimmune conditions has been shown to correlate with 
increased mortality in patients with CHH (Vakkilainen, et al. 2018). Using a different 
approach, we confirmed these findings in Study IV, which included 80 out of 104 patients 
from the previous report and showed that autoimmunity is a risk factor for 
immunodeficiency-related death. 
Importantly, many risk factors for adverse outcomes in CHH can be identified early in 
childhood. These include Hirschsprung disease, birth length score less than -4.0 SD, 
pneumonia in the first year of life and symptoms of combined immunodeficiency. These 
features can predict a more severe disease course and should prompt consideration of 
aggressive treatment strategies, including HSCT.  
After the introduction of newborn screening for SCID using T cell receptor excision circles, 
some patients with CHH can present for the evaluation and consideration of HSCT. In 
asymptomatic cases, if clinicians and caregivers opt for watchful waiting, patients should be 
closely followed-up to identify specific features associated with adverse outcome and 
necessity of HSCT should be re-evaluated as needed. 
We could not identify risk factors for the development of fatal or non-fatal malignancy in our 
cohort when patients with all registered malignancies were included into analysis. This 
suggests that skin cancer and lymphoma arise from different mechanisms in CHH. In addition, 
some of the malignancies reported in our patients (for example, thyroid carcinoma) are not 
associated with PID. 
When cases of lymphoma were analyzed, recurrent pneumonia in childhood was identified 
as the only risk factor. However, we also described patients with CHH and clinically 
asymptomatic immunodeficiency who developed malignancies. Hence, while profound 
immunodeficiency, illustrated by recurrent RTI, associates with lymphoma, other 
mechanisms underlie the development of malignancies in mildly symptomatic patients. 
Further studies should identify these pathways on the molecular and cellular levels. 
 
6.5. Implications for management 
 
Our demonstration of shorter telomeres in patients with CHH provides several potential 
therapeutic implications. Severe hypoplastic anemia in CHH can be life-threatening and can 
require HSCT (Taskinen, et al. 2013, Williams, et al. 2005). The pathogenesis of bone marrow 
failure in CHH can involve impaired telomere machinery and therapeutic strategies can be 
adopted from other telomeropathies. Androgens have been used successfully to treat anemia 
in patients with dyskeratosis congenita (Calado and Cle 2017), and their efficacy in bone 
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marrow failure in CHH should be investigated. Subjects with short telomere syndromes are 
radiation-sensitive and prone to develop treatment-related toxicity with conventional HSCT 
regimens and other T cell cytotoxic drugs (Wagner, et al. 2018). Therefore, our findings should 
be explored further in order to evaluate the necessity of the adjustment of therapeutic 
regimens in patients with CHH. 
Infections and malignancies are the most common causes of death in patients with PID 
(Mortaz, et al. 2016) and this holds true also for those with CHH. Management decisions 
should thus focus on prevention and proper treatment of infections, as well as careful follow-
up for early detection of malignancies. In addition, we demonstrated for the first time, that 
lung diseases contribute significantly to the mortality of patients with CHH. Therefore, 
aggressive treatment approaches should be implicated, and patients’ management should 
include the prevention of RTI, timely detection of bronchiectasis and consideration of HSCT 
in cases of lung disease unresponsive to other therapies. 
Pulmonary management in patients with CHH should aim at prevention of lung infections and 
bronchiectasis. This should include proper immunization against pathogens causing 
respiratory infections, including pneumococcal and annual influenza vaccines. Patients 
should be advised against smoking and, in case of proven respiratory allergies, should avoid 
aeroallergens. In addition, addressing co-morbidities influencing pulmonary status, such as 
chronic rhinosinusitis, obesity, skeletal deformities, gastroesophageal reflux and vitamin D 
deficiency, is important to prevent lung morbidities (Chang, et al. 2018). 
The treatment of the existing bronchiectasis focuses on hindering further lung damage and 
on proper treatment of exacerbations. Pulmonary rehabilitation and exercise have 
demonstrated efficacy in adults with bronchiectasis (Chang, et al. 2018). Antibiotics, including 
macrolides, are the cornerstone of therapy and prevention of flares in patients with 
bronchiectasis irrespective of underlying pathology (Chang, et al. 2018). Prolonged treatment 
with clarithromycin has been successful in CHH children with lung disease, resulting in the 
improvement of bronchiectasis in one of the patients (Bailly-Botuha, et al. 2008).  
While IGRT is of undoubted benefit in patients with symptomatic hypogammaglobulinemia, 
the commencement of this therapy is questionable in those with normal IgG levels, including 
the majority of patients with CHH (Table 2). Only several case reports describe the clinical 
course of CHH patients after initiation of IGRT for recurrent RTI (Ammann, et al. 2004, Horn, 
et al. 2010, Moshous, et al. 2011). Of the five subjects (four with hypogammaglobulinemia), 
only two benefited from therapy, other three continued to experience recurrent infections, 
including one with a fatal outcome. However, suboptimal immunoglobulin dosing may have 
affected poor clinical response described in these studies. For example, in a 4-year-old boy, 
the dose of 0.4 g/kg of intravenous immunoglobulin was used by Ammann at al, which 
resulted in trough levels of IgG between 5.1 and 6.0 g/l (Ammann, et al. 2004).  
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Occasionally, IGRT and prophylactic antibiotics induce regression and even resolution of 
bronchiectasis in primary antibody deficiencies, but this cannot be shown consistently (Baris, 
et al. 2011, Gregersen, et al. 2010). IGRT reduces the rates of pulmonary infections in patients 
with humoral immunodeficiency but does not prevent the decline in lung function (Baumann, 
et al. 2018). Our findings of higher IgG levels in patients with bronchiectasis suggest that 
management decisions have to be made on individual basis and cannot be based on low IgG 
levels alone. However, IGRT can be insufficient to prevent lung damage and death from end-
stage lung disease in patients with CHH, and HSCT should be considered in severe cases. 
Importantly, the progression of bronchiectasis in patients with CHH can be halted by HSCT 
(Bordon, et al. 2010). 
The outcome of patients with CHH after HSCT has been reported in a series of 3, 6, 13 and 16 
patients with survival rates of 100%, 100%, 83% and 63% respectively (Bordon, et al. 2010, 
Guggenheim, et al. 2006, Ip, et al. 2015, Kavadas, et al. 2008). Mortality after HSCT was 
attributed mostly to infections, including disseminated adenovirus, cerebral mucormycosis, 
pneumococcal sepsis and pseudomonal pneumonia (Bordon, et al. 2010, Ip, et al. 2015). The 
majority of surviving patients achieved full reconstitution of B and T cell numbers and 
function (Guggenheim, et al. 2006, Ip, et al. 2015) and the quality of life was improved 
(Bordon, et al. 2010, Ip, et al. 2015). As in other PID, early HSCT can be life-saving in CHH, 
while HSCT performed after the onset of opportunistic infections can be fatal (Moshous, et 
al. 2011).  
HSCT in patients with PID decreases the risk of malignancies (Kamani, et al. 2011). No cancer 
cases have yet been reported in patients with CHH who had received HSCT and had been 
followed-up for up to 22 years (Bordon, et al. 2010, Guggenheim, et al. 2006, Kavadas, et al. 
2008). Therefore, HSCT offers a preventive approach if prognostic indicators could select 
candidates for HSCT before the development of malignancies. 
With the advent of newborn screening for SCID, some CHH patients with low numbers of T 
cell receptor excision circles, reflecting poor T cell production, will be diagnosed very early in 
life. The optimal management of such cases remains debatable. Early HSCT may provide cure 
for the underlying immunodeficiency before the potential onset of severe infections. 
However, given the mild clinical course of some patients with CHH and good survival after 
HSCT in adults with PID (Fox, et al. 2018), a more conservative approach could be possible, 
with careful observation and timely detection of disease progression. Therefore, implication 
of the knowledge of risk factors for the development of severe complications is crucial to 
detect subjects most likely to benefit from HSCT. 
Traditionally, HSCT has been rarely used in Finnish patients with CHH, and no HSCT has been 
performed in our study subjects. However, HSCT has been considered for some of these 
patients late in the disease course, but, unfortunately, was declined by clinicians due to the 
poor health condition of the subjects. Therefore, HSCT should be considered early for selected 
patients with multiple risk factors for adverse outcome detected in our studies. 
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The possible clinical implications of our studies in the management of patients with CHH are 
presented in Table 18.  
Table 18. Implications in the management of Finnish patients with cartilage-hair hypoplasia. 
Research findings Implications for management 
Certain features associate with morbidity and mortality in 
patients with CHH. Patients with CID show the most 
severe clinical course. 
Assess risk factors for early mortality to choose 
appropriate management strategies, for 
example, consider HSCT in patients with CHH 
and CID. 
Hirschsprung disease associates with immunodeficiency-
related mortality in CHH. 
Acknowledge that Hirschsprung disease is one 
of the markers of severe disease course in CHH. 
Birth length score less than -4.0 standard deviation 
associates with mortality. Patients with shorter birth 
length develop malignancies at an earlier age. 
Acknowledge that shorter birth length carries 
poor prognosis in CHH. 
In addition to CID and Hirschsprung disease, pneumonia 
in the first year of life, and recurrent pneumonia and 
autoimmunity in adulthood associate with 
immunodeficiency-related death in CHH. 
Acknowledge that several other risk factors 
associate with adverse outcomes in CHH. 
Infections and respiratory diseases are among the most 
common causes of death in patients with CHH. 
Consider aggressive management (prophylactic 
antibiotics, IGRT, HSCT) in patients with 
recurrent RTI and pulmonary complications. 
The majority of patients with CHH, even severely 
symptomatic, present with normal or elevated serum IgG 
levels. The most common pattern and etiology of 
infections are similar to infections in antibody-deficient 
patients. Patients show high prevalence of bronchiectasis 
and die of infections and lung disease. Many patients 
demonstrate specific antibody deficiency and/or 
decreased counts of B cells, including low memory B cells. 
Consider antibiotic prophylaxis and/or IGRT 
based on clinical manifestations, irrespectively 
of serum IgG levels. 
Patients can develop adult-onset immunodeficiency or 
malignancy that can be fatal. 
Follow-up all patients, even completely 
asymptomatic. 
Lung changes, mostly bronchiectasis, are highly prevalent 
in CHH, and respiratory symptoms should not be 
attributed to asthma until other underlying causes are 
excluded. Lung MRI findings correlate well with HRCT 
results and decrease radiation exposure. 
Perform lung imaging by HRCT and/or MRI in 
patients with chronic respiratory symptoms. 
Patients have increased incidence of malignancies, mostly 
lymphoma and skin cancer. Early detection of lymphoma 
can result in successful therapy with complete resolution. 
Screen for cancer regularly (clinical 
examination, abdominal ultrasound). 
Skin cancer is common in CHH and is limited to sun-
exposed skin areas. Actinic keratosis is the strongest risk 
factor for skin malignancy in patients with CHH.  
Educate patients about the importance of sun 
protection to reduce the risk of skin cancer. 
Pulmonary complications are highly prevalent in CHH. Advise patients against smoking. 
CHH cartilage-hair hypoplasia, CID combined immunodeficiency, HRCT high-resolution computed tomography, 
Ig immunoglobulin, IGRT immunoglobulin replacement therapy, MRI magnetic resonance imaging, RTI 
respiratory tract infections.  
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7. STRENGTHS AND LIMITATIONS 
 
The major strength of our research is the novelty of the reported data. Our studies were first 
to describe the prevalence of bronchiectasis in the general CHH population, the detailed data 
on T and B cell subpopulations and vaccine responses, telomere length, and, most 
importantly, long-term follow-up data and risk factors for mortality in patients with CHH. 
Other advantages of our studies include large numbers of participating patients, allowing for 
adequate sample size for statistical analysis. The inclusion of adult patients provided novel 
valuable information on the disease course in CHH patients surviving into adulthood. The 
accuracy of data collection was maximized in Study IV by using all available information from 
all Finnish health registries, as well as by thorough analysis of all patient records.  
The major limitation of studies I-III is the retrospective nature of clinical data. We overcame 
this in Study IV which produced prospective and long-term follow-up health data. 
Further limitations include possible selection bias, as we recruited patients regardless of their 
clinical presentation. One can speculate that the patients who decided to take part in the 
study may have experienced more symptoms and agreed to participate in order to receive 
medical evaluation and treatment. However, most of the patients in our cohort reported no 
current complaints during visits.  
Another limitation of our studies I-III is the use of a single laboratory measurement per 
patient. Results of immunologic tests in patients with CHH fluctuate and predicting clinical 
course based on cross-sectional laboratory evaluation may be challenging. The participation 
of patients from all age groups could influence the analysis as the symptoms may cumulate 
and the results of laboratory tests may differ in older patients. The latter was overcome by 
age-appropriate reference values and multiple regression analysis.  
In Study I, the small number of healthy controls may increase the risk of bias. Another 
limitation is the use of RTL, which did not allow for the estimation of telomere length 
distributions and for detection of critically short individual telomere ends. Measurement of 
telomeres from peripheral blood with PCR has high variability, in part due to fluctuations of 
telomere length in leukocytes (Alder, et al. 2018). However, our results have been confirmed 
in later study in which a different measurement method was applied (Aubert, et al. 2017). 
We acknowledge the limitations of our definitions of humoral or combined 
immunodeficiencies based on the reported symptoms only, but we feel that, given the 
diversity and fluctuation of laboratory results in patients with CHH, this may have some 
practical implications. In Study IV, patients categorized as having CID showed higher 
mortality. This suggests that our clinical categorization of immunodeficiency correlates well 
with prognosis of the patients and can be adopted in clinical practice. 
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8. FUTURE PROSPECTS 
 
Our results provide several new research directions. Lung disease contributes significantly to 
the morbidity and mortality of patients with CHH. Further studies should address the 
prevention and treatment options of bronchiectasis, including the possible benefit of IGRT. 
Asymptomatic patients with bronchiectasis and fibrosis-like changes detected on imaging 
should be followed-up to investigate the progression of lung changes. Lung MRI should be 
repeated to evaluate the applicability of this imaging modality in the follow-up of pulmonary 
status. 
Future studies should investigate the functional consequences of impaired telomere 
maintenance in CHH and its potential clinical implications. Assessment of telomere length in 
children with CHH combined with long-term follow-up would evaluate the applicability of 
telomere length as a prognostic factor in CHH. 
Further research is required in the selection of patients for HSCT, including the applicability 
of risk factors detected in our studies. In addition, prospective studies are necessary to 
evaluate the benefit of early HSCT in mildly or moderately symptomatic CHH patients with 
positive newborn screening for SCID.  
Before applying the risk factors for adverse outcomes identified in our studies to the general 
CHH population, the validation of these risk factors is required in Finnish and non-Finnish 
patients with CHH. Evidence-based guidelines on the management of patients with CHH are 
urgently needed to optimize treatment decisions and improve survival. Follow-up on the 
mortality rates after the implementation of the new management recommendations would 
demonstrate their impact. 
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9. CONCLUSIONS 
 
Our studies provided valuable insights into clinical and immunological phenotypes of CHH, 
guiding the follow-up and management of patients with CHH. We presented previously 
unavailable data on clinical and immunologic features of older adults with CHH. We described 
novel findings of high prevalence of specific antibody deficiency and various abnormalities in 
B and T cell subpopulations. We could not identify any significant correlations of clinical 
features with laboratory parameters, and our data suggest that in some cases management 
decisions should be based on clinical manifestations. 
We demonstrated for the first time the consequences of RMRP mutations on telomere 
functioning by detecting shorter telomeres in patients with CHH, especially children. These 
findings can explain the pathogenesis of various clinical features in CHH and have important 
clinical implications. 
We reported a high prevalence of bronchiectasis in the general CHH population and showed 
that pulmonary evaluation was indicated in all, even asymptomatic, patients with CHH. We 
compared the performance of lung MRI with HRCT and confirmed that MRI can be implicated 
in the assessment of pulmonary changes in CHH. 
We demonstrated that patients with CHH had high mortality not only due to infections and 
malignancies, but also from respiratory diseases. We provided long-term follow-up data and 
described several patterns of disease course, including adult-onset immunodeficiency and 
the development of malignancies in previously asymptomatic patients. These data call for 
regular follow-up and screening for cancer in all individuals with CHH, irrespective of the 
degree of immunodeficiency. 
Our data on the risk factors for adverse outcomes in CHH provide clinicians with valuable tool 
for evaluation of prognosis and we suggest implication of our results for the management of 
Finnish patients with CHH. 
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